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Abstract
In this review, we report on breast cancer’s molecular features and on how high
throughput technologies are helping in understanding the dynamics of tumorigenesis
and cancer progression with the aim of developing precision medicine methods. We first
address the current state of the art in breast cancer therapies and challenges in order to
progress towards its cure. Then, we show how the interaction of high-throughput
technologies with in silico modeling has led to set up useful inferences for promising
strategies of target-specific therapies with low secondary effect incidence for patients.
Finally, we discuss the challenge of pharmacogenetics in the clinical practice of cancer
therapy. All these issues are explored within the context of precision medicine.
Keywords: Hallmarks, Omics, Profiling, Therapy, Stem cell, Signaling networks, Tumor
heterogeneity, Pharmacogenetics
Background
Breast cancer (BC) is a global disease; it is the most common cancer in women (ac-
counting for 25 % of all cancers), with nearly 281,840 estimated new cases, and 40,290
estimated deaths in 2015 in the US population (http://seer.cancer.gov), which account
for ~320 million people. BC is also becoming an increasingly urgent problem in low-
and middle-income countries, such as Brazil where government estimates BC as the
major malignant neoplasia in women and the main cause of death from cancer in the
country. This fact has been associated with increased life expectancy, urbanization, and
high-risk cancer-causing behaviors such as tobacco smoking [1].
The shortcomings of one-size-fits-all approach (an approach that is standard and not
tailored to individual needs) to treatments are well reflected in the disappointing out-
come of current chemotherapies, where drug agents directed at an individual target
often show limited efficacy and safety due to factors such as off-target side effects, by-
pass mechanisms and cross-talk across compensatory escape pathways [2] due to gen-
ome destabilization and signaling rewiring. Because, malignant rewiring is induced by
apparently random genomic perturbation, therapy improvement has to go through pre-
cision medicine (PM).
By contrast to stratified medicine (SM), which consists in indicating a drug for a
population according to a specific molecular alteration, PM aims to indicate a treat-
ment individually [3]. Thus, PM is a medical model that proposes the customization of
healthcare, with medical decisions, practices, and/or products being tailored to the in-
dividual patient. In this model, diagnostic testing is often employed for selecting appro-
priate and optimal therapies based on the context of a patient’s genetic profile or other
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molecular or cellular analysis [4, 5]. At the moment SM is the dominant model; it is di-
vided into two different types of molecular screening programs: basket trials and um-
brella trials. The basket trials test the effect of a single drug on a molecular alteration
in a variety of cancers while the umbrella trials assess the effect of different drugs in
different molecular alterations either in one or several tumours [3].
Despite still disappointing results partly due to incorrect or imprecise prevailing
views and technology limitations, PM remains an indispensable route to decrease the
toxicity of cancer treatment and to increase its benefit to patients. A mutation-oriented
approach is not expected to solve cancer therapy because if genome destabilization is
effectively due to these mutations, cellular dysregulation results to a greater degree
from genome destabilization than from such mutations. Recent progresses in high
throughput generation of genome, transcriptome, proteome, and interactome data as
well as in silico data mining offer the possibility of unprecedented high precision diag-
nosis at prices that become affordable. The integration of sciences through informatics
and mathematical modeling constitutes a new opportunity to improve cancer therapies
through PM. Thus, it is the aim of this report to review the traditional approach that is
given to BC treatment and the benefit that breakthrough technologies, modeling and
data manipulations may provide to traditional limitations in the prospective of PM ap-
plied to BC.
Review
Incidence of breast cancer and prevention
Cancer incidence varies among countries mainly according to lifestyle, which explains as
much as 75-85 % of cancer etiology, with the most significant parameters being: physical
inactivity, obesity, extensive working hours, intensive exposure to carcinogens, hormonal
contraceptive use, postmenopausal hormone replacement therapy, nulliparity, late age at
first birth, and enhanced alcohol consumption [6]. Lifestyle’s influence on cancer likeli-
hood has been demonstrated by statistics from people migrating from their native country
to an adopted country starting to mimic the risk profile and cancer incidence of their
adopted country (especially USA). For instance, populations consuming high levels of
plant derived foods have low incidence rates of various cancers particularly in Southern
European (Mediterranean countries) compared to Northern European countries. Simi-
larly, populations in South East Asian countries have a much lower risk of developing nu-
merous cancers compared to their more industrialized, Western counterparts [7].
Countries with lower cancer incidence were associated with a nutrition mostly based on
vegetables, fruits and fishes rather than on red meat and animal fats. The compounds that
have been most cited as being cancer protective include those that belong to phenolics
comprised of at least 8,000 chemical species throughout the plant kingdom with their
main representative belonging to shikimic acid, phenylpropanoid and flavonoid biosyn-
thetic pathways [8–10]. The main action of these compounds is to prevent cancer devel-
opment by promoting anti-oxidant and anti-inflammatory effects as well as inducing cell
cycle arrest, cell survival and apoptosis or programmed cell death [7]. Because of the
pleiotropic effect of plant compounds, the exact contribution of a diet based on plant
products to cancer prevention is difficult to unwrap [11]. Examples of plant compounds
used in cancer therapy are: curcumin, genistein, resveratrol and catechins.
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Mammary gland complexity and cell type diagnosis
The mammary gland is a complex organ constituted by two tissue compartments, i.e.
epithelium and stroma, which undergoes cycles of proliferation, differentiation and
apoptosis in response to local and endocrine signals. It is the highly dynamic epithe-
lium that undergoes major functional differentiation upon pregnancy to produce milk
in response to local and endocrine signals. The epithelium of the mammary gland is
made of luminal and basal/myoepithelial cells. Luminal cells line the ductal lumen and
secrete milk upon terminal differentiation into lobulo-alveolar cells while basal/myoe-
pithelial cells are lodged just below luminal cells and ensure ductal contractility to re-
lease milk [12]. Breast duct are also infiltrated with stem cells (SC) tightly regulated to
produce all cellular elements that make up breast ducts and, therefore, play a critical
role in normal gland development and cycling. SCs normally undergo asymmetric div-
ision to generate a copy of the original cell and a progenitor one that will suffer differ-
entiation [13].
Stroma is a connective tissue whose main constituents, from a BC prospective, are
adipocytes, fibroblasts, and endothelial cells; it is the mammary fat pad that supports
the extensive system of ducts and alveoli. The functional mammary gland results from
a succession of distinct stages under steroid and peptide hormonal control: (i) cyclical
production of ovarian estrogen and progesterone accelerates ductal growth and branch-
ing during puberty, (ii) prolactin and placental lactogens control the proliferation and
maturation of the alveolar compartment during pregnancy, and (iii) systemic concen-
tration of prolactin and growth hormone decline with the increased pressure resulting
from cessation of milk removal as well as loss of suckling stimuli [14].
Following mammogram diagnosis, BC is usually classified primarily by its histological
appearance (Table 1). Most BCs are derived from the epithelium compartment and are
considered malignant according to their differentiation grade, which can be differenti-
ated (low grade), moderately differentiated (intermediate grade), and poorly differenti-
ated (high grade) as the cells progressively lose the features seen in normal breast cells.
Poorly differentiated cancers have the worse prognosis. BC cells have receptors on their
surface, in their cytoplasm and nucleus that can be used for molecular classification by
histopathology and simple immunohistochemical procedures. Three primarily investi-
gated receptors are the estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2, also known as ERBB2) because their status
Table 1 State of hormonal receptors in several cell lines used as molecular markers for breast
cancer diagnosis
Cell line Histological subtype ER/PRa HER2b EGFRc CK5-6d
MCF10A Control 0 0-1+ 2+ +
MCF-7 LAe 6 0-1+ 1+ -
T-47D LA >0 2+ - -
ZR-75-1 LA 3-4 2+ 1+ -
BT-474 LBf 0/8 3+ 1+ -
BT-20 TNg 0 0-1+ 2+ -
MB-231 TN 0 0-1+ 1+ -
MB-468 TN 0 0 3+ -
aER/PR Estrogen/Progesterone receptor, bHER2 Human epidermal growth factor receptor; c EGFR epidermal growth factor,
dCK5-6 Cytokeratin 5/6; eLA luminal A, fLB Luminal B, gTN triple-negative
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informs the physician in regard to how to proceed with specific therapies. When cancer
cells express estrogen receptors, they depend on estrogen for their growth, so they can
be treated with antagonist drugs (e.g. tamoxifen) to block estrogen effects on ER signal-
ing cascade, and generally have a better prognosis. The majority of cells co-express ER
and PR, which means that cells expressing one or both receptors are hormone
receptor-positive (HR+) cells [15]. HER2+ cancer cells respond to biological agents
such as the monoclonal antibody trastuzumab used in combination with conventional
chemotherapy [16]. Cells that do not express these three receptor types are called
triple-negative (TN); the lack of addressable molecular targets in these tumors is chal-
lenging and no FDA approved TN-specific treatments are currently available. Although
they frequently express receptors for other hormones, such as androgen and prolactin,
cells with a luminal phenotype are rarely observed in basal-like BCs [17]. TN patients
have the worst prognosis [18] (as shown in Fig. 1). A number of studies have demon-
strated that TN can be subclassified into six subtypes [19]. Notably, the three main
markers above have been shown to have a high negative predictive value, but a limited
positive predictive value. Hence, the development of molecular tools with better pre-
dictive power for patient outcome and response to treatment has long been a subject of
great interest in translational research.
Solid tumors represent a heterogeneous environment regarding access to oxygen and
nutrients; thus their growth depends on the physical location of their malignant cells
relative to these factors under the prevailing conditions. As a model of solid tumors,
floating sphere-forming assays (mammosphere) are broadly used to test SC activity in
tissues, tumors and cell lines. Spheroids originate from a small population of cells with
SC features, which are able to grow in a suspension culture and behaving tumorigeni-
cally in mice [20]. Because the classification of malignant cells is a key parameter for a
successful development of a therapy, considerable efforts are being invested in molecu-
lar characterization of malignant cells. In particular, breast cancer stem cells (BCSC)
generated substantial interest because they are thought to play the role of a common
Fig. 1 Kaplan-Meier graph illustrating the relative patient 5-years survival by tumor type according to time
after treatment (modified from [17])
Carels et al. Theoretical Biology and Medical Modelling  (2016) 13:7 Page 4 of 46
ancestor for most tumor cells. In that regard, markers for BCSC would allow the rou-
tine blood diagnosis diminishing the necessity for invasive biopsies [21]. Actually, none
of the known markers are specific for BCSC, and only new cell surface marker combi-
nations may improve the reliability, identification, and enrichment of BCSCs [22]. Clus-
ters of differentiation (CD) are antigens expressed on cell surface that are used to
diagnose cellular populations according to their type and function using specific anti-
bodies. Today, more than 360 different CDs have been identified. The surface cell
markers epithelium cancer adhesive molecule (Ep-CAM) and CD49f (α-6 integrin) were
investigated in that context. It was found that the combination Ep-CAMhigh/CD49fneg
cells represent the differentiated luminal cells, while the combination Ep-CAM-/low/
CD49f+ phenotype characterize mainly the basal fraction of the human epithelial cells
[23]. However, it has also been shown that the majority of BC cells have a luminal Ep-
CAMhigh/CD49f+ phenotype, and the identification of CD44high/CD24low status significantly
improves flow cytometry diagnosis of BC forming SCs [24]. Thus BCSC classifica-
tion allowed to show that epithelial population of basal A progenitor cells (Ep-
CAM-/low/CD49f+), luminal B progenitor cells (Ep-CAMhigh/CD49f+), and luminal
differentiated C cells (Ep-CAMhigh/CD49f−) differ in their ability to form mammo-
spheres and colonies in such a way that A > B while C does not possess these abil-
ities [22, 24]. At the moment, the very low blood concentration of SC is a hurdle
for liquid biopsy, but a new development in nanotechnology suggests that mechan-
ical and optoplasmonic transduction will soon allow the detection of cancer bio-
markers in serum at ultra-low concentrations such as ~10−16 g/ml [25].
Carcinogenesis process and consequences for patients
The process of carcinogenesis can be broadly categorized into three distinct tumor
phases: initiation, promotion and progression, i.e., metaplasia, dysplasia and anaplasia,
respectively. Tumor initiation includes the transformative process by which a cell de-
differentiates itself or changes from one phenotype to another to enter into hyper-
proliferative and inflammatory processes. The prevailing model for cancer development
is that mutations in genes for tumor suppressors and oncogenes lead to cancer. In mam-
mals, DNA mutation cannot be avoided since their somatic cells are known to use the
microhomology-mediated end joining (MMEJ) to repair double-strand breaks in DNA
and this mechanism is known as an error-prone repair pathway. In MMEJ, a homology
of 5–25 complementary base pairs is sufficient to align both paired strands, but mis-
matched ends (flaps) are usually present. MMEJ removes the extra nucleotides (flaps)
where strands are joined and then ligates the strands to create an intact DNA double
helix. MMEJ almost always involves at least a small deletion compared to the original
sequence [26]. By extension of the causative effect of mutations in suppressor or onco-
genes on tumor induction, it has also been proposed that mutations in master genes
(controlling cell division) cause chromosome replication defects with changes in gene
expression in such a way that affected cells produce too little or too much of a specific
protein. If chromosomal aberrations affect the amount of one or more proteins control-
ling the cell cycle such as growth factors or tumor suppressors, it may result in tumor
development. Excessive methylation of genes involved in cell cycle, DNA repair, and
apoptosis may also lead to cancers since DNA methylation affects gene expression.
Thus, different mechanisms affecting the genes involved in normal regulation of a cell
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or of their surrounding DNA may contribute to tumor induction or development. Can-
cer is essentially a disease of the regulation system of a cell that directs it to uncon-
trolled division and growth. The evolution of a cell toward cancer is a cumulative
process that occurs on a phenotypic spectrum of increasingly disordered premalignant
stages. The classic mathematical model of cell progression through tumoral stages de-
veloped by Armitage and Doll suggested that 5–8 rate-limiting events are required to
generate such patterns [27].
Solid tumors whether in vitro or in vivo, are not undifferentiated masses of cells.
They include necrotic regions composed of cells in quiescent state (either slowly grow-
ing or not growing at all), and regions where cells proliferate quickly. Cell’s decision to
become quiescent or proliferating is thought to depend on both nutrient and oxygen
availability as well as on the presence of tumor necrosis factors produced by necrotic
cells that somehow inhibit further tumor growth. Mathematical models were proposed
for the growth of spheroids in vitro [28–30] as well as of tumors in vivo [31].
Tumor progression involves the stroma contribution to the initiation of angiogenesis,
which is the vascularization process required to sustain the energetically inefficient
tumor growth under hypoxic conditions. More exactly, angiogenesis involves the prolif-
eration and migration of endothelial cells (EC) in pre-existing vessels, while vasculo-
genesis involves the mobilization of bone-marrow-derived endothelial progenitor cells
(EPC) into the bloodstream. In its broad sense, angiogenesis refers to the sum of angio-
genesis and vasculogenesis. Once EPCs home in the tumor site, they may subsequently
differentiate into ECs and contribute to the genesis of vascular structures. As far as the
vascularization process is able to keep pace with demands of a growing tumor, the
tumor growth rate may remain unaffected [32].
Some cancer cells acquire the ability to penetrate the walls of lymphatic and/or blood
vessels, and circulate through the bloodstream to other sites and tissues in the body. At
some point, they re-penetrate the vessels or walls and continue to multiply if their new
hosting location is compatible with their natural environment and eventually form an-
other clinically detectable secondary or metastatic tumor. Metastasis requires specific
adhesive properties necessary for malignant cell dispersion [33]. Ultimately, incurable
cancer leads to cachexia (a profound and marked state of constitutional disorder associ-
ated with a catastrophic and irreversible weight loss). The biophysical modeling of
cachexia suggests that this disease state is due to a negative energy balance induced by
anaerobic metabolism and excessive tumor mass at the cost of increased muscle wast-
ing. In multiple metastatic cancers, the tumor cost could exceed patient needs to
stabilize energy balance through nutrition support and bring him/her to exhaustion
and accelerated demise [34].
Consequence of tumor heterogeneity on cancer evolution and drug
resistance
Whole-cancer genomes carry thousands to tens of thousands of somatic mutations, the
vast majority of which probably have no biological relevance [35]. Cancer evolves dy-
namically as clonal expansions supersede one another driven by shifting selective pres-
sures, mutational processes, and disrupted cancer genes. The compilation of
mutational signatures from model systems exposed to known mutagens or perturba-
tions of the DNA maintenance machinery allowed the setting up of an extensive
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catalogue of mutations in 30 of the most common cancer types. The procedure uncov-
ered more than 20 signatures of processes that mutate DNA, most of them due to the
AID/APOBEC family of cytidine deaminases responsible for C > T transitions on CpG
dinucleotides [36]. CpG dinucleotides are hot spots of cytosine methylation whose de-
methylation may promote transition to thymine due to errors in the process. This
process promotes the erosion of the genomic GC level; an opposite process named
kataegis ensures an increase of the GC level by preferential incorporation of cytosine in
an AT-rich context [37].
As different patterns of genomic instability have distinct genomic footprints, it is pos-
sible to interrogate sequencing and copy-number data to examine how genomic in-
stability shapes tumor growth and evolution. Chromosome gain or loss is more likely
to have functional consequences than point mutations, most of which are neutral [38].
The gains and losses of whole chromosomes or chromosome arms are well-recognized
features of BC cells probably caused by mis-segregation of chromosomes during cell
division [39]. The onset of large-scale chromosomal gains only starts after at least 15–
20 % point mutations accumulate, but thereafter continues steadily in many tumors.
However, aneuploid rearrangements occur early in tumor evolution and remain rather
stable as the tumor masses clonally expand. In contrast, point mutations evolve grad-
ually, generating extensive clonal diversity [40]. Ultimately, genome doubling can be
also observed after, rather than before, the onset of chromosomal instability at later
stages in disease progression [41]. Plants and animals that exhibit the process of gen-
ome doubling are generally endowed with a metabolic benefit known as hybrid vigor
[42], which may in part explain the metabolic success of malignant cells.
In case of clonal sweep whereby a new clone takes over and entirely replaces the an-
cestral population, one observes a homogeneous cell population succeeding the previ-
ous one; this situation is an example of linear evolution. By contrast, if a new clone
fails to outcompete its predecessor(s), a degree of heterogeneity will be observed [43],
which has motivated pathologists to routinely examine multiple sections of a tumor to
classify it by its highest locally observed grade [44]. When branched tumor evolution
occurs, it results in extensive subclonal diversity [45]. It seems that in real conditions,
one observes a mix of both processes since every tumor has a dominant subclonal
lineage, representing more than 50 % of tumor cells (Fig. 2). Actually, there is approxi-
mately a 90 % likelihood of detecting a fully clonal mutation, a 60 % chance of detect-
ing a mutation found in 50 % of tumor cells, and a 5 % chance of detecting a mutation
in 25 % of tumor cells. Subclonal diversification is prominent, and most mutations are
found in just a fraction of tumor cells. Minimal expansion of these subclones occurs
until many hundreds to thousands of mutations have accumulated, implying the exist-
ence of long-lived, quiescent cell lineages capable of substantial proliferation upon ac-
quisition of enabling genomic changes [41].
A key landmark in tumor evolution is that the most-recent common ancestor cell
lineage has the full complement of somatic mutations found in all derived tumor cells.
All extant cancer cells in the analyzed sample can trace a genealogy back to the initial
egg cell that started the process of uncontrolled division. The most-recent common an-
cestor appears early in the carcinogenesis process with the consequence that much of
the carcinogenesis process is devoted to subclonal diversification. One may conclude
from this situation that the dominant subclone is separated from the most-recent
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common ancestor by many hundreds to thousands of point mutations, and that there
is minimal evidence of significant clonal expansion before the accumulation of all mu-
tations in the dominant subclone [41].
A corollary of the branched evolution of tumoral cell lineages is the high likelihood
of drug resistance occurring in one of them, which indicates the need for longitudinal
tumor sampling over the course of the disease and throughout treatment because the
subclone that influences a disease outcome may not be detectable in a single biopsy
[38]. In fact, subclones can behave in functionally distinct ways after exposure to
chemotherapy and dormant resting cells surviving cytotoxic exposure can be positively
selected by the treatment promoting future relapse when the patient is supposed to be
disease free [46].
Increasing evidences in a variety of tumor types suggests that cells with properties of
SCs are more resistant to various commonly used chemotherapeutic treatments [47].
Their persistence helps to explain the cancer recurrence following apparently successful
treatment. BCSCs seem to be able to exhibit certain forms of dormancy enabling latent
cancer cells to persist for years or even decades after treatment and suddenly to emerge
again. Malignant cell response to therapy has been modeled by Demidenko [48] and
drug resistance resulting from tumor heterogeneity can be rationalized in agreement
with what is known from microbial evolution. According to the classic view of ‘survival
of the fittest’, tumor cells will acquire mutations, and selection pressures will facilitate
the outgrowth of some clones, but not others. Mutations provide a source of variability
whose selection is applied through environmental constraints in such a way that a
Fig. 2 Model of tumor heterogeneity evolution over time (modified from [39])
Carels et al. Theoretical Biology and Medical Modelling  (2016) 13:7 Page 8 of 46
population explores the landscape of possible adaptation to the environmental chal-
lenges by ‘trial and error’ through its individual representatives [49]. On rare occasions,
mutations provide a fitness advantage to fuel adaptive evolution and the increased mu-
tation rate comes at the cost of increased mutational load in the genome. If beneficial
mutations under strong selection occur rarely, one expects selective sweeps to drive
these mutations to fixation with low resulting diversity according a linear evolution pat-
tern. However, if these mutations occur frequently, they coexist within a population
and promote its diversity according to a branched evolution pattern. By contrast, weak
selection can drive diversity through the accumulation of small-effect deleterious muta-
tions, with detrimental overall population fitness effects unless sufficient gain of a few
beneficial mutations counterbalances the global figure. Exposure to drugs creates a
bottleneck favoring the few clones that may randomly possess a mutation that confers
resistance to the selective drug. Thus, drug treatments are expected to reduce popula-
tion heterogeneity [44].
All these concepts together reinforce the notion that cancer treatment should be con-
sidered as a shift away from the one-size-fits-all approach, toward one in which health-
care is based on the intra- and inter-tumor heterogeneity.
Hallmarks of cancer
The concept of a cancer hallmark tends to rationalize the complexity of neoplastic dis-
eases in properties common to all cancer forms and that govern the transformation of
normal into malignant cells. Hallmarks are acquired functional capabilities that allow
cancer cells to survive, proliferate, and disseminate; these functions are acquired in dif-
ferent tumor types via distinct mechanisms and at various times during the course of
multistep tumorigenesis. According to Hanahan and Weinberg [50], cancer hallmarks
include:
(i) Sustaining proliferative signaling allowing malignant cells to stimulate their own
growth. Normal cells require external growth signals (growth factors) to grow and
divide. Growth factors bind cell-surface receptors, typically containing intracellular
tyrosine kinase domains. The latter proceed to emit molecular signals via branched
intracellular signaling pathways that regulate progression through the cell cycle as
well as cell growth. By contrast, cancer cells can generate their own growth sig-
nals. Over-expressed growth factor receptors or mutated signaling protein may
continuously stimulate division without the need of any growth factors in an auto-
crine proliferative stimulation. The numerous signaling molecules affecting cancer
cells operate as nodes in interaction networks forming integrated circuits that are
reprogrammed derivatives of the circuits operating in normal cells. Defects in
negative feedback loops that normally operate to dampen various types of signaling
to ensure homeostatic regulation of intracellular circuitry are capable of enhancing
proliferative signaling [51]. Defects in the mammalian target of rapamycin
(mTOR) signaling pathway may also promote cell proliferation [52];
(ii) Growth suppressors, i.e., resistance to paracrine inhibitory signals from their
surrounding environment in the extracellular matrix and on the surfaces of
neighboring cells that might otherwise stop their growth [53, 54]. These inhibitors
act on the cell cycle clock, by interrupting cell division in the interphase.
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Ultimately, signals of growth inhibition are funneled through the retinoblastoma
protein (pRB), which prevents the inappropriate transition from G1 (where cells
synthesize mRNA and proteins in preparation for subsequent mitosis) to S (the
cellular phase of DNA replication) [55]. If a pRB is damaged through mutation, its
homing cell can start to divide uncontrollably [56];
(iii) Evading cell death, i.e., resistance to programmed cell death (apoptosis). The
apoptotic machinery can be divided into sensors (IGF-1R and IL-3), which monitor
the cell for abnormal behavior, and effectors (receptors of FAS and TNF-α ligands),
which cause apoptosis through caspase proteases. Cell is progressively disassembled
and contracts into an almost-invisible corpse that is soon consumed, both by its
neighbors and by specialized phagocytic cells, upon apoptosis induction. The p53
tumor suppressor protein elicits apoptosis in response to DNA damage, and is a
major protector of genome integrity. Tumors may escape apoptosis either by p53 in-
activation or by increasing expression of anti-apoptotic regulators (Bcl-2, Bcl-xL) or
of survival signals (Igf1/2), by down-regulating pro-apoptotic factors (Bax, Bim,
Puma), or by short-circuiting the extrinsic ligand-induced death pathway. Alterna-
tively, excessive signaling by oncoproteins such as RAS, MYC, and RAF can counter-
act the induction of senescence and/or apoptosis by cells [57];
(iv) Enabling replicative immortality. Normal mammalian cells have an intrinsic
program, the Hayflick limit, that limits their multiplication to about 60–70
doublings that can be overcome in cancer cell by pRB and p53 tumor suppressor
disabling and lead to immortalization. The clock that counts cell doubling is
telomere sequences at chromosome tips by losing DNA at each cell cycle [58]. In
many malignant cells, telomerase is up-regulated and telomeres are longer that in
normal cells and seemingly involved in unlimited proliferation [59, 60]. However,
in the human breast [61], the premalignant lesions do not express significant levels
of telomerase and are marked by telomere shortening and non-clonal chromo-
somal aberrations suggesting that the initial involvement of p53 is disabled. Thus,
the delayed telomerase activation stabilizes mutant genomes and confers the un-
limited replicative capacity that cancer cells need in order to clonally expand;
(v) Inducing angiogenesis, i.e., stimulating the growth of blood vessels to supply
nutrients and oxygen to tumors. The blood vessels produced within tumors by
chronically activated angiogenesis are typically aberrant with tumor
neovasculature marked by precocious capillary sprouting, convoluted and
excessive vessel branching, distorted and enlarged vessels, erratic blood flow,
micro-hemorrhaging, leakiness, as well as abnormal levels of endothelial cell prolif-
eration and apoptosis [62]. Angiogenesis is induced by the binding of regulators,
such as endothelial growth factor-A (VEGF-A) and thrombospondin-1 (TSP-1), to
receptors displayed by vascular endothelial cells. The regulation of these factors
can be modulated both by hypoxia and oncogene signaling [63].
(vi) Activating invasion of local tissue and metastasis or malignant cell spread to
distant sites. A set of pleiotropic transcriptional factors (including Snail, Slug,
Twist, and Zeb1/2) that orchestrate the epithelial-mesenchymal transition (EMT)
(a means by which transformed epithelial cells can acquire the abilities to invade,
to resist apoptosis, and to disseminate) and related migratory processes are
expressed in various combinations in a number of malignant tumor types. They
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have been shown to be involved in programmed invasion [64, 65]. Cancer cells at
the invasive margins of certain tumors may undergo EMT suggesting that these
cancer cells are subject to micro-environmental stimuli distinct from those re-
ceived by malignant cells within the tumor body [66]. The multi-step process of
invasion and metastasis is presented as a succession of cellular biological changes
beginning with: (i) the local invasion of surrounding stroma; (ii) the malignant cell
intravasation into nearby blood and lymphatic vessels, transit of cancer cells
through lymphatic and hematogenous systems; (iii) the escape of malignant cells
from their lumina into parenchyma of distant tissues (extravasation); (iv) the for-
mation of micro-metastases; and (v) the growth of micro-metastatic lesions into
macroscopic tumors [67]. Concerning secondary site colonization by metastatic
cells, it is worthwhile that micro-metastases that have successfully disseminated
may never progress to macroscopic metastatic tumors [67, 68]. Matrix-degrading
proteases are necessary to facilitate invasion into stroma, across blood vessel walls,
and through normal epithelial cell layers. Metastatic cells must mimic normal
cell–cell interactions, through cell–cell adhesion molecules (CAMs) and integrins.
E-cadherin, which is expressed on epithelial cells [69], transmits antigrowth signals
and is therefore a widely acting suppressor of invasion and metastasis that needs
to be overcome by cancer cells in order to progress. The role of contextual signals
in inducing an invasive growth capability (often via an EMT) implies the possibility
of reversibility since cancer cells that have disseminated from a primary tumor to
a distant site may no longer benefit from the favorable context of the activated
stroma available in the primary tumor. In the absence of these signals, malignant
cells may revert to a non-invasive state. Thus, malignant cells that have undergone
an EMT during initial invasion and metastatic dissemination may pass through the
reverse process of mesenchymal-epithelial transition (MET) [49]. Each type of
metastatic cell needs to develop its own set of ad hoc solutions to the problem of
thriving in a new microenvironment [70]. These adaptations might require hun-
dreds of distinct signaling programs;
(vii)Abnormal metabolic pathways. Most cancer cells use abnormal metabolic
pathways to generate energy. A hypoxic tumor microenvironment resulting from
inadequate blood supply is a common feature of solid tumors. Hypoxia is a major
driving force of malignant progression. It inhibits apoptosis, induces angiogenesis
and the anaerobic metabolic switch, activates the EMT program, and promotes
invasiveness and metastatic dissemination [71]. Glycolysis is the metabolic
pathway that converts glucose to lactate. Under aerobic conditions, normal cells
successively process glucose to pyruvate via glycolysis in the cytosol and to carbon
dioxide in the mitochondria via oxidative phosphorylation; under anaerobic
conditions, glycolysis is favored and relatively little pyruvate is dispatched to the
oxygen-consuming mitochondria. Tumors generally have a high uptake of glucose
relative to normal tissues. Cancer cells compensate for the ~18-fold lower effi-
ciency of ATP production released by glycolysis relative to mitochondrial oxidative
phosphorylation by up-regulating glucose transporters. Glycolytic fueling has been
shown to be associated with activated oncogenes (e.g., RAS, MYC) and mutant
tumor suppressors (e.g., p53) [72, 73]. The high demand for glucose together with
lactate secretion, even in the presence of adequate oxygen, has been termed the
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Warburg effect [74]. Some tumors have been found to contain two subpopulations
of cancer cells that differ in their pathways of energy supply with one subpop-
ulation relying on the Warburg effect while the other subpopulation preferen-
tially utilizes the lactate produced by their neighbors to generate energy
through a part of the citric acid cycle [75, 76]. Glutamine may also be con-
verted into lactate in cancer cells in vitro [77]. The tumor anaerobic metabol-
ism of glucose and glutamine is a potential driver of muscle protein
catabolism, as muscle is the major metabolic source of carbon for gluconeo-
genesis and glutamine biosynthesis. Thus, the inefficient energy tumor metab-
olism occurs at the cost of muscle loss and cachexia [34];
(viii)Evading the immune system, malignant cells appear to be invisible to immune
system. Evidence suggests that the immune system operates as a significant barrier
to tumor formation and progression. In genetically engineered mice that are
immune-deficient, tumors arise more frequently and/or grow more rapidly than in
the immune-competent controls [78, 79]. Highly immunogenic cancer cells seem
to evade immune destruction by disabling challenging components of the immune
system. For example, cancer cells may paralyze infiltrating CTLs and NK cells, by
secreting TGF-β or other immune-suppressive factors [80, 81].
(ix) Unstable DNA. As outlined above, cells accumulate mutations and
chromosomal abnormalities, which worsen as the disease progresses. Genomic
defects induced by malfunctioning genes of DNA-maintenance machinery con-
fer inability to: (i) properly detect DNA damage and activate repair machinery,
(ii) repair damaged DNA, (iii) inactivate or intercept mutagenic molecules be-
fore they have damaged the DNA [82], and (iv) maintain telomeric DNA [58].
From a genetic perspective, these DNA-maintenance machinery genes behave
much like tumor suppressor ones. The lack of genomic integrity surveillance
induced by p53 deactivation may allow the survival of initial telomere erosion
by other incipient neoplasias and attendant chromosomal breakage-fusion-
bridge cycles. The deletions and amplifications of chromosomal segments
induced by this process evidently promote genome mutability as well as muta-
tion in oncogenes and tumor suppressor genes [58].
(x) Inflammation, the chronic tumor infiltration provides tumorigenic factors.
Necrotic cells become bloated and explode, releasing their pro-inflammatory sig-
nals into the local tissue micro-environment in contrast to apoptotic cells that do
not. As a consequence, necrotic cells can recruit inflammatory cells of the immune
system [83, 84] attracted by associated necrotic debris. Incipient neoplasias as well
as potentially invasive and metastatic tumors may gain an advantage by tolerating
some degree of necrotic cell death in order to recruit tumor-promoting inflamma-
tory cells that bring growth-stimulating factors to the surviving cells. Chemo-
attractants recruit the pro-invasive inflammatory cells rather than producing
the matrix-degrading enzymes themselves. It is the macrophages at the tumor
periphery that supply matrix-degrading enzymes such as metallo-proteinases
[85] and cysteine cathepsin proteases [86]. Therefore, they promote local tissue
invasion by tumor cells. In addition, tumor-associated macrophages (TAM)
also supply epidermal growth factor (EGF) to BC cells, while the cancer cells
reciprocally stimulate the macrophages in such a way that their concerted
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interactions facilitate malignant cells intravasation into the circulatory system
and metastatic dissemination [87].
In addition to malignant cells, tumors benefit from their micro-environment manipu-
lation, which complicates the hallmark system [88]. Normal cells, which form tumor-
associated stroma are active participants in tumorigenesis rather than passive by-
standers; as such, these stromal cells contribute to the development and expression of
certain hallmark capabilities [89, 90]. Among stromal components that are active tumor
helpers, one may note three major cell types: angiogenic vascular cells (which supply
growth factors promoting multiple hallmark capabilities), infiltrating immune cells
(which supply mitogenic signals to cancer cells and proteolytic enzymes that release
bioactive mitogenic agents from the ECM), and cancer-associated fibroblastic cells
(which secrete mitogenic epithelial growth factors). Paracrine and juxtacrine mitogenic
signals supplied by stromal cell types may potentially be involved in different tumor
types at virtually any stage of tumorigenesis and progression, ranging from the initi-
ation of aberrant proliferation to the development of adaptive resistance to therapies
targeting such driving oncogenic signals [88].
Molecular targets for breast cancer treatments
As outlined above, BC resembles a Darwinian evolutionary system, with branching tra-
jectories emerging from mutations and epigenetic changes. Such a complexity suggests
that the disease control needs multi-drug cocktails. A promising strategy is to target
the key phenotype features of BC cells, such as hypoxia, excessive glycolysis, angiogen-
esis and dedifferentiation. All these together might be targeted to transpose the hurdle
of intra-tumor heterogeneity. Thus far, more than 15 different classes of target proteins
have already been identified in BC along with evidence supporting drug combinations
for cancer control, which deserve to be briefly listed below and are more extensively
reviewed by Zardavas et al. [91]. In the state-of-the-art of modern clinical treatment,
most specific drugs target proteins that belong to the signaling pathway or to trans-
membrane receptors providing inputs to that pathway (Fig. 3).
The fibroblast growth factor (FGF) signaling pathway induces cancer cell proliferation,
apoptosis evasion, facilitation of an invasive phenotype and induction of angiogenesis. There
are 18 FGF ligands for four trans-membrane receptors (FGFR1–4). Activation of the path-
way is associated with the consecutive activation of phosphoinositide 3-kinase (PI3K)/ pro-
tein kinase B (AKT)/mTOR, mitogen-activated protein kinases (MAPK), signal transducers
and activators of transcription (STAT), and ribosomal protein S6 kinase 2 (RSK2) signaling.
The FGF pathway has been implicated in a broad range of human malignancies and pro-
motes cancer progression in tumors driven by FGF/FGFR oncogenic mutations or amplifi-
cations responsible for tumor neo-angiogenesis and targeted treatment resistance, thereby
supporting a strong rationale for anti-FGF/FGFR agent development [92, 93].
The insulin-like growth factor (IGF) and their receptors play pivotal roles in cellular
signaling transduction and thus regulate cell growth, differentiation, apoptosis, trans-
formation and other important physiological processes. The IGF pathway includes
three trans-membrane receptors: insulin-like growth factor 1 receptor (IGF-1R), insulin
receptors (IRα and IRβ), their three ligands: IGF-I, IGF-II, insulin, and the six regulatory
proteins: insulin-like growth factor-binding proteins (IGFBP1-6). The IGF-1R is mainly
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engaged in the Ras/MAPK and the PI3K/AKT pathways, and also forms cross-talks
with the epidermal growth factor receptor (EGFR) pathway. IGF pathway is activated in
more than 90 % of BC cases and is a potential target in metastatic BC. Combination of
mTOR and IGF inhibitors has been shown to have a synergistic effect by inhibiting the
AKT activation mediated by IGF-1R. There are many agents developed for the inhib-
ition of IGF-1R, which are categorized into monoclonal antibodies, small molecule in-
hibitors and so on [94, 95].
The PI3K/AKT/mTOR signaling pathway is a hub that interconnects different onco-
genic receptor tyrosine kinases (RTKs) with other oncogenic agents to control cell pro-
liferation. RTKs activate: (i) the pathway (HER2 for human epidermal growth factor
receptor-2, FGFR1, IGF-1R); the PI3K catalytic (p110α and p110β) and regulatory
(p85α) subunits; the downstream PI3K effectors: AKT1 and AKT2; (ii) the PI3K activa-
tor: Kirsten rat sarcoma homolog (KRAS); and (iii) the negative PI3K regulators: phos-
phatase and tensin homolog (PTEN) and inositol polyphosphate 4-phosphatase B
(INPP4B). TN cells are sensitive to simultaneous PI3K and mTOR inhibition. The
mTOR kinase is a coordinator of cell growth and metabolism that lies both upstream
and downstream of the PI3K pathway. mTOR activation results in the inhibition of
PI3K signaling via negative feedback of some cancer cells signaling circuitry. mTOR
senses and integrates diverse nutritional and environmental cues, including growth fac-
tors, energy levels, cellular stress, and amino acids [96]. It couples these signals to pro-
mote cellular growth by phosphorylating substrates that potentiate anabolic processes
such as mRNA translation and lipid synthesis, or limit catabolic processes such as au-
tophagy (autophagy is the organelle’s breakdown by a cell to supply the energy metab-
olism under starvation conditions). Thus, when mTOR is inhibited as is the case when
applying rapamycin, the associated loss of negative feedback results in an increased ac-
tivity of PI3K and its effector AKT/PKB, thereby balancing the anti-proliferative effects
Fig. 3 Map of key proteins in signaling pathways for the investigation of cancer therapies
Carels et al. Theoretical Biology and Medical Modelling  (2016) 13:7 Page 14 of 46
of mTOR inhibition induced by rapamycin [52]. Clinicians are currently faced with a
wide array of clinical trials investigating a multitude of inhibitors with different mecha-
nisms of action, being used both as single agents and in combination with other therap-
ies [97].
The MAPK/extracellular signal-regulated kinases (ERK) signaling pathway is also
known as the Ras-Raf-MEK-ERK pathway because it constitutes a chain of proteins
that communicates a phosphorylation signal acting as an on- or off- switch from a
trans-membrane protein receptor to the nuclear DNA. MAPKs are involved in direct-
ing cellular responses to a diverse array of stimuli, such as mitogens, osmotic stress,
heat shock and pro-inflammatory cytokines. They regulate cell functions including pro-
liferation, gene expression, differentiation, mitosis, cell survival, and apoptosis [98]. The
MAPK/ERK1/2 signalling pathway is often dysregulated in BC and induces cellular pro-
liferation and survival, differentiation, metastatic dissemination, as well as angiogenesis.
Further characterization of the RAS-MAPK molecular regulation in malignant cells
and of the acquired resistance to RAF inhibitors will facilitate development of novel
combination therapies [99].
The MET (hepatocyte growth factor receptor - HGFR) pathway is another complex sig-
nalling network, which promote tumor progression through multiple oncogenic actions
such as induction of cellular proliferation, angiogenesis, as well as invasion and metastatic
dissemination through the activation of intracellular transduction systems (PI3K/AKT/
mTOR, MAPK, STAT and SRC, which is a non-receptor protein tyrosine kinase) [100].
Cyclin-dependent kinases (CDKs) are a group of serine/threonine kinases that inter-
act with specific cyclin proteins to regulate cell cycle progression. CDK bind a regula-
tory protein called cyclin. Without cyclin, CDK has little kinase activity and only the
cyclin-CDK complex is an active kinase. CDKs are serine-threonine kinases, i.e., they
phosphorylate their substrates on serines and threonines. Cancer cells override normal
cell cycle checkpoints that function to halt the cell cycle as a result of DNA damage or
molecular defects in the mitotic spindle. CDK inhibitors with high selectivity (particu-
larly for both CDK4 and CDK6), in combination with patient stratification, have re-
sulted in substantial clinical activity [101].
The Hedgehog signaling pathway has been originally described as specific to embryonic
cells and is required for proper embryo development. This pathway is also found active in
pluripotent BCSCs. The pathway takes its name from its polypeptide ligand, an intercellu-
lar signaling molecule called Hedgehog (Hh) found in Drosophila. Sonic hedgehog (SHH)
is the best-studied ligand of the vertebrate pathway. When SHH reaches its target cell, it
binds to the Patched-1 (PTCH1) receptor, which inhibits Smoothened (SMO), a down-
stream protein in the pathway that determines the fate of vertebrate limb development.
Activation of the hedgehog pathway has been implicated in the BC development [102].
The Hh signaling pathway may represent a potential therapeutic target for patients with
refractory pancreatic cancer. A potent Hh inhibitor can successfully inhibit tumor growth
and invasiveness in vitro and can become a promising drug. However, in clinical trials, it
has not been easy to verify the effectiveness of an Hh signaling inhibitor yet [103].
The Wnt signalling pathway is another regulator of stem cells in mammalian organ-
isms, which is commonly dysregulated in human cancers. The Wnt name comes from
the int/Wingless family from Drosophila that was renamed the Wnt family and int1 be-
came Wnt1. Wnt signaling pathways are activated by the binding of a Wnt-protein
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ligand to a Frizzled family receptor, which passes the biological signal to the protein
Dishevelled inside the cell [104]. The canonical Wnt pathway leads to regulation of
gene transcription, the non-canonical planar cell polarity pathway regulates the cyto-
skeleton that is responsible, among other functions, for the cell shape. In embryos,
Wnt controls body axis patterning, cell fate specification, cell proliferation, and cell mi-
gration and has been found to be activated in BC [105]. Drug-discovery platforms and
new technologies have facilitated the discovery of agents that can alter Wnt signalling
in preclinical models, thus setting the stage for clinical trials in humans [106].
Breast cancer therapies
Drug therapy
They are five stages (0 to IV) to describe BC. Briefly and roughly, (i) stage 0 is used to de-
scribe non-invasive BCs, (ii) stage I describes BC invading normal surrounding breast tis-
sue, (iii) stage II describes BC invading lymph nodes, (iv) stage III describes BC invading
in the lymph nodes near the breastbone and (v) the metastic stage IV that describes inva-
sive BC spreading beyond the breast and nearby lymph nodes to other organs of the body.
Chemotherapy for early stage (stage I and II) BC is not usually given as a single drug.
Drugs are more commonly used in combination with one another because drug combina-
tions have been shown to be more effective than monotherapies. Because of cytotoxic
drug based therapies, the different combinations of drugs used to treat BC tend to have
similar effectiveness. However, different chemotherapy combinations may be preferred for
women with BC that has spread to the lymph nodes (node positive), locally advanced BC
or inflammatory BC. Women with HER2+ BC may also be given biological therapy to-
gether with certain chemotherapy combinations.
The most common chemotherapy combinations used to treat BC are listed below:
 AC - doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan, Procytox)
 AC – Taxol: doxorubicin and cyclophosphamide, followed by paclitaxel (Taxol)
 TC - docetaxel (Taxotere) and cyclophosphamide
 TAC (or DAC): docetaxel, doxorubicin and cyclophosphamide
 FAC (or CAF): cyclophosphamide (orally), doxorubicin and 5-fluorouracil (Adrucil,
5-FU)
 CEF: cyclophosphamide (orally), epirubicin (Pharmorubicin) and 5-fluorouracil
 FEC: cyclophosphamide, epirubicin and 5-fluorouracil
 FEC – T: cyclophosphamide, epirubicin and 5-fluorouracil, followed by docetaxel
 CMF – IV: cyclophosphamide (intravenous), methotrexate and 5-fluorouracil
 CMF – PO: cyclophosphamide (orally), methotrexate and 5-fluorouracil
 Taxol – FAC: paclitaxel, then followed by cyclophosphamide, doxorubicin and 5-
fluorouracil
 Doxorubicin and docetaxel
 EC – GCSF: epirubicin and cyclophosphamide, with filgrastim
 Docetaxel and carboplatin (Paraplatin, Paraplatin AQ)
 Gemcitabine (Gemzar) and docetaxel
 Gemcitabine and paclitaxel
 Capecitabine (Xeloda) and docetaxel
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Certain chemotherapy drugs may be used alone to treat advanced or metastatic BC.
They may also be given to women who have BC that is no longer responding to other
treatments. This is because single drugs have fewer side effects than drug combinations.
Drugs used to treat BC in the clinic are listed below together with their molecular
targets:
 Ado-Trastuzumab Emtansine - targeting the Her2/neu receptor
 Adrucil (Fluorouracil, 5-FU) - an anti-metabolite
 Afinitor (Everolimus) - an mTOR inhibitor
 Aredia (Pamidronate Disodium) - a biophosphonate
 Arimidex (Anastrozole) - an estrogen synthesis inhibitor
 Aromasin (Exemestane) - an estrogen synthesis inhibitor
 Cisplatin - a DNA intercalator
 Clafen (Cyclophosphamide) - a DNA alkylating agent
 Doxorubicin Hydrochloride - a DNA intercalator
 Ellence (Epirubicin Hydrochloride) - a DNA intercalator
 Eribulin Mesylate - a microtubule inhibitor
 Etoposide (Vesepid, VP-16) – a topoisomerase II inhibitor
 Fareston (Toremifene) - a selective estrogene receptor modulator (SERM)
 Faslodex (Fulvestrant) - a selective estrogene receptor degrader (SERD)
 Femara (Letrozole) - an estrogen synthesis inhibitor
 Folex (Methotrexate) - an anti-metabolite and an anti-folate
 Fulvestrant - an estrogen receptor antagonist
 Gemzar (Gemcitabine Hydrochloride) - a nucleoside analog
 Herceptin (Trastuzumab) - targeting the Her2/neu receptor
 Ibrance (Palbociclib) - selective inhibitor of the cyclin-dependent kinases CDK4 and
CDK6
 Ixempra (Ixabepilone) - a microtubule stabilizer
 Kadcyla (Ado-Trastuzumab Emtansine) - targeting the Her2/neu receptor
 Megace (Megestrol Acetate) - a progesterone receptor agonist
 Mitomycin (Mutamycin) - a DNA cross-linker
 Nolvadex (Tamoxifen Citrate) - an estrogen receptor antagonist
 Perjeta (Pertuzumab) - a HER2 dimerization inhibitor
 Taxol (Paclitaxel) - a microtubule stabilizer
 Taxotere (Docetaxel) - a microtubule stabilizer
 Thiotepa - a DNA alykalting agent
 Tykerb (Lapatinib Ditosylate) - a protein kinase inhibitor
 Velban (Vinblastine Sulfate) - a microtubule destabilizer
 Velsar (Vinblastine Sulfate) - a microtubule destabilizer
 Vinorelbine (Navelbine) - a microtubule destabilizer
 Xeloda (Capecitabine) - a metabolite of 5-FU
 Zoladex (Goserelin Acetate) - a gonadotropin releasing hormone superagonist
Most of the drugs listed above target tubulin and microtubules, are anti-metabolites, or
target specific hormone receptors. The latter class is used in those subtypes of BC in
which hormone receptors are known to be up-regulated (estrogen, progesterone, HER2).
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Hormone therapy
Hormone therapy is a systemic therapy, which inhibits the growth of hormone-
sensitive tumors by blocking the body’s ability to produce hormones or by interfering
with a hormone mechanism of action. This therapy might be useful as a neoadjuvant
treatment, however, it is most often used as an adjuvant therapy to help in reducing the
post-surgery relapse risk and also in the case of metastases. Hormone therapy is helpful
for HR+ BC, but it does not help patients whose tumors are hormone receptor negative
(both ER- and PR-). Several strategies have been developed to treat HR+ BC:
(i) Ovarian shutdown or removal: The ovaries are the main source of estrogen in
premenopausal women; estrogen levels in these women can be reduced by
eliminating or suppressing ovarian function, which is called ovarian ablation.
Ovarian ablation can be done permanently or temporarily. In a permanent way by
oophorectomy or by treatment with radiation [107]. In the temporarily way, ovarian
function can be suppressed by drug therapy using gonadotropin-releasing hormone
(GnRH) agonists. These drugs interfere with feedback regulation by the pituitary
gland that stimulates ovaries to release estrogen. The data from currently published
clinical trials of GnRH agonists in adjuvant settings for premenopausal women with
endocrine-sensitive BC support benefit to patients [108]. Ovarian shutdown by drug
therapy or surgical removal is used only in premenopausal women. Examples of
ovarian shutdown drugs that have been approved by the U.S. Food and Drug Ad-
ministration (FDA) are goserelin (Zoladex®) and leuprolide (Lupron®).
(ii)Blocking estrogen production: Aromatase is the enzyme that converts testosterone
to estradiol, which is found in the body’s muscle, skin, breast and fat. Examples of
aromatase inhibitors (AIs) approved by the FDA are anastrozole (Arimidex®) and
letrozole (Femara®), both of which temporarily inactivate aromatase, and
exemestane (Aromasin®), which permanently inactivates aromatase. Diaby et al.
[109] showed that, in both early stage and advanced or metastatic BC, newer AIs
have proved to be cost-effective compared to older treatments.
(iii)Blocking estrogen’s effects: Several types of drugs modulate estrogen receptors:
 Selective estrogen receptor modulators or down-regulators (SERMs or SERDs)
have a competitive binding to estrogen receptors. Examples of SERMs approved by
the FDA are tamoxifen (Nolvadex®), raloxifene (Evista®), and toremifene (Fareston®).
Tamoxifen has been used for more than 30 years to treat HR+ BC, and can be
given for 5 to 10 years after surgery to lower the likelihood of relapse. It also lowers
the emergence risk of a new BC in the other breast. Because SERMs bind to
estrogen receptors, they can potentially not only work as estrogen antagonists, but
also as estrogen agonists according to the tissues considered. For example,
raloxifene acts to prevent bone loss and to improve lipid profiles by decreasing total
and LDL cholesterol, but it may also block some estrogen effects, such as those
inducing breast and uterine cancers.
 Other anti-estrogen drugs, such as fulvestrant (Faslodex®) compete for estrogen
receptor as estrogen antagonist. Upon ER binding by fulvestrant, the complex is
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targeted for destruction by the immune system. Fulvestrant, unlike SERMs, has no
estrogen agonist effect reported.
There are three cases in which hormone therapy should be used for BC treatment: (i)
adjuvant therapy for early-stage BC, (ii) treatment of advanced or metastatic BC, and
(iii) neoadjuvant treatment of BC. Tamoxifen has been approved by the FDA for the ad-
juvant hormone treatment of premenopausal and postmenopausal women with ER+
early-stage BC, while anastrozole and letrozole have been approved in postmenopausal
women. A third AI is exemestane, which has been approved as adjuvant treatment of
early-stage BC in postmenopausal women who have previously received tamoxifen.
Most women who received adjuvant hormone therapy are advised to take tamoxifen
every day during 5 years in order to reduce the likelihood of a BC relapse [110].
A number of drugs are approved or are in clinical trials for the treatment of HR+
metastatic BCs. Investigations have shown that tamoxifen is effective in treating women
with metastatic BCs; toremifene is also approved for this use. Fulvestrant can be used
in postmenopausal women with metastatic ER+ BC after treatment with other anti-
estrogens. Turner et al. [111] showed that the combination of palbociclib (a CDK4 and
CDK6 inhibitor) and fulvestrant to treat advanced BCs has a better outcome than ful-
vestrant used alone. Anastrozole and letrozole can be given to postmenopausal women
as initial therapy for metastatic HR+ BCs. These two drugs, as well as the aromatase in-
hibitor exemestane, can also be used to treat postmenopausal women with advanced
BCs whose disease has worsened after tamoxifen treatment.
The use of hormone therapy to treat BC before surgery (neoadjuvant therapy) has been
studied in clinical trials [110]. The goal of neoadjuvant therapy is to reduce the size of a
breast tumor in order to allow breast conservation upon surgery. Data from randomized
controlled trials have shown that neoadjuvant hormone therapies, in particular AIs, can
be effective in reducing the size of breast tumors in postmenopausal women.
Endocrine therapy has significantly improved the outcome of patients with early- and
advanced-stage HR+ BCs. However the success of hormone therapy is limited and some
patients with early-stage or a metastatic stage of the disease may experience relapse or
sustained disease progression. Hormonal therapy remains a controversial area with a
number of unanswered questions, such as tumor resistance, patient refractoriness, opti-
mal therapy duration, and type of complementary drugs for suitable combinations [112].
Immunotherapy
The heterogeneous expression of tumor antigens within the primary tumor or its me-
tastases, the modification of antigenic profile during the tumor progression, and the
low levels of the antigen major histocompatibility complex proteins, as well as the low
levels of other co-stimulatory proteins necessary to generate a strong immune response
can explain the low immunogenicity level of tumors. Moreover, the tumor microenvir-
onment releases immune-suppressive factors that make the antigen presentation diffi-
cult and that have a negative impact on the immune response [113]. In addition,
tumors may evade immune destruction by blocking endogenous immune checkpoints
that normally terminate immune responses after antigen activation. To face the low im-
munogenicity, the immuno-surveillance hypothesis has been refined through the
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concept of immune-editing where T cells from patients can be genetically engineered
to express a novel T cell receptor or chimeric antigen receptor to specifically recognize
a tumor-associated antigen and thereby selectively kill the corresponding tumor cells
[114]. The expected benefit of immunotherapy is the specific lysis of antigen-positive
cells, leaving healthy tissues intact. By using gene transfer technologies, T cells can be
genetically engineered to express a unique high-affinity T cell receptor (TCR) or a
chimeric antigen receptor (CAR), both of which confer novel tumor antigen specificity.
An adequate number of genetically engineered T cells can therefore be produced
in vitro for back transfer to the patient. In contrast to a TCR, which recognizes a pep-
tide fragment of an antigen presented by an HLA molecule on the surface of target
cells, a CAR molecule recognizes an intact cell surface antigen. Hence, tumor cell rec-
ognition is HLA-independent so there is no restriction in terms of patient selection.
However, the requirement for the tumor-associated antigen to be a cell surface antigen
excludes all mutated intracellular proteins from being targeted by CAR T cell-based
therapy. The ScFv portion of the CAR molecule is generally derived from a mouse
MAb. This may evoke immune responses and potential clearance of CAR-engineered T
cells. To avoid this possibility, fully human CARs can be constructed [115]. Genetically
engineered T cells may exert toxicity on healthy cells. Moreover, they have the potential
to last for a long time in the host and even expand in number. Therefore, any adverse
toxicity may worsen over time. This is a particular concern when T cells are engineered
to resist the physiological signals that are exploited by many cancers to subvert tumor
immune recognition and effector function. A suicide gene can be included in the genet-
ically engineered T cells along with the CAR transgene. Cancer therapy using genetic-
ally engineered T cells is still in its infancy and the methodological diversity of TCRs
and CARs preparation as well as the different preconditioning cytokine regimens will
require careful optimization to be truly effective [114].
Nanoparticle therapy
Nanoparticles are characterized by self-assembly, stability, drug encapsulation and bio-
compatibility as a result of their material composition. Nanoparticles are typically pre-
pared using polyethylene glycol (PEG) as a coating material at the nanoparticle surface
in order to reduce protein adsorption and complement activation [116]. The suspen-
sion of nanoparticles is very stable, and can be lyophilized. They have the potential to
overcome multifactorial tumor resistance to chemotherapy due to their size between 1
and 100 nm [117]. Because aberrant morphology of their vascularization, a unique fea-
ture of solid tumors is their leaky blood vessels and defective lymphatic drainage that
promotes the delivery and retention of macromolecules or nanoscale particles. Nano-
particles can be constructed at a certain size for enhanced permeability and retention
effects, which is the basis for the use of nanoparticles in cancer. A careful design of
nanoparticle formulation can overcome barriers posed by the tumor microenvironment
and result in better treatment effectiveness. Pharmacologically active concentrations of
an anticancer drug in a tumor tissue are often reached at the expense of massive body
contamination with the consequence of deleterious side effects for the patient. Second-
generation nanoparticles are supposed to better control deleterious side effects of drugs
because of optimized intra-tumor drug delivery.
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The challenge in nanoparticle technology is the optimization of their tumor targeting
because of the progressive transformation of malignant cell membrane receptors due to
the accumulation of genome alterations. It has been shown that 100 nm-diameter
nanoparticles can passively enter tumor tissues, increasing selectivity of anticancer drug
delivery at the tumor site, while markedly reducing drug accumulation and toxicity in
many susceptible healthy tissues [118]. However, second-generation nanoparticles,
which present surface decoration with ligands for proteins overexpressed on the surface
of malignant cells are expected to substantially increase their uptake due to their in-
creased target specificity. Unfortunately, the proper diagnosis of expressed compatible
proteins on the surface of malignant cells is a bottleneck that deserves further investi-
gation. The development of various nanoparticles with different ligands now offers a
larger choice to target tumors characterized by drug resistance [119]. The use of ligands
that bind specifically to malignant cell receptors may help to reduce the dose-limiting
cytotoxicity of drugs and also enable drugs to bypass resistance mechanisms via cyto-
plasm release through endocytosis. Several clinical trials are ongoing to test the com-
bination of: (i) monoclonal antibodies (bevacizumab, pertuzumab, trastuzumab), (ii)
chemotherapy (doxorubicin, cyclophosphamide, paclitaxel, carboplatin, capecitabine,
doxorubicin hydrochloride, filgrastim), and (iii) nanoparticles to improve BC treatment
for early and advanced-stages (see https://clinicaltrials.gov). Another strategy that has
been proposed to regulate the expression of protein targets in malignant cells has in-
volved siRNA [120–122], but the successful target down-regulation depends on their
half-life [120] and gene therapy (clustered regularly interspaced short palindromic re-
peats - CRISPR) could be necessary. However, CRISPR technology could only be envis-
aged if nanoparticle tumor specificity is guaranteed because permanent gene
deactivation in normal cells might be another source of problems.
High throughput technologies to assist precision therapies
The spatio-temporal organization of a developing organism requires carefully orches-
trated sequences of cellular differentiation events triggered by decisions made by indi-
vidual cells about their fate. Cell fate decisions are stochastic and are not reproducible
at the single-cell level, but they result in highly consistent, almost deterministic pat-
terns at the level of the whole cell population. The question of how this macroscopic
order arises from a disordered microscopic behavior is reminiscent of statistical me-
chanics in physical systems. Cellular proliferation is punctuated by sequences of deci-
sions that guide cell differentiation into diverse types and cell fates. These decisions are
driven by chemical and mechanical signals and are highly organized in space and time,
leading to well-defined macroscopic patterns, tissues and organs, in a highly reprodu-
cible manner [123]. In a developing embryo, SCs might be seen as drifting down a dif-
ferentiating hill, representing the progression towards a developed organism, where
they encounter branching points at which cells must decide to follow a fate over an-
other. In culture, SCs are somehow trapped in some self-sustainable regime of pluripo-
tent or multipotent states along the differentiation landscape. An analogy between cells
in culture and statistical mechanics allows the systematic investigation of their response
to controlled signals [124]. Using the standard terminology of statistical mechanics,
these signals can thus be considered control parameters, and their effect can be mea-
sured in terms of a macroscopic observable, which is an output variable such as the
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proportion of cells within a population with a given phenotype. Cell fate decisions are
associated with diverse sets of microscopic rules, defined by the genes (evaluated
through genome data) and proteins involved in individual states of regulation (evalu-
ated through transcriptome and proteome data) and by interactions (evaluated through
interactome data; [125]) between them. Biological processes are considered as complex
networks of interactions among numerous cell components rather than independent in-
teractions involving only a few molecules. Because the multi-dimensional complexity of
these processes involves large sample sizes, high throughput technologies are necessary to
describe their time related dependencies. High throughput technologies decisively helped
in developing stratified oncology. SM means analyzing large groups of cancer patients in
order to predict which treatments these cancer patients are most likely to respond to. It
involves looking in detail at the cancer cells and their genetic make up. Nowadays, science
is able to classify cancers according to their heterogeneity and main molecular markers
and the stratified oncology knowledge is progressively integrated with patient therapy to
improve disease outcome considering features such as personal medical history, physio-
logical index, molecular status of tumors, which represents the arsenal of PM tools.
Genome sequencing
Cancers are interlinked to each other through a number of pathways, which are altered
in different diseases [126]. Next generation sequencing (NGS) has been a significant
technological advance for improving the understanding of malignant neoplasm because
cancer is basically viewed as a genome disease. As outlined above, genome sequencing
has allowed the characterization of chromosome abnormalities as gene deletion and
amplification, translocation or sequence inversion as well as an epigenetic landscape.
The most significant impact of next-generation sequencing on cancer genomics has
been the ability to re-sequence, analyze and compare the matched tumor and normal
genomes of a single patient. With the significantly reduced cost of sequencing, it is
now possible to sequence multiple patient samples of a given cancer type. NGS sequen-
cing is useful to understand the affected pathways behind cancer development. This re-
quires a preliminary investigation to map genes that potentially lead to tumor
development (oncogenes) since many mutations may occur without carcinogenic con-
sequences. This calibration step typically involves: (i) comparison with other sequenced
genomes (via dbSNP) and to other resources for variant discovery such as the 1000 Ge-
nomes Project (www.1000genomes.org), followed by (ii) comparison of remaining vari-
ant sites between the tumor and the normal genome. Another caveat of this approach
is the decision whether a mutation diagnosis is a false positive, which tends to result
from incorrect interpretation, a false negative, which is harder to evaluate and mainly
appears as a lack of sequencing coverage or is actually correct (true positive). Informa-
tion about the prevalence of any mutation in a cell population allows one to infer how
early in the path toward cancer development that particular mutation occurred [127].
Exome is a part of the genome formed by exons, which are the protein-coding por-
tions of genes. The whole exome sequencing information can reflect the mutations of
the protein-coding region in the genome and depict the causal relationship between
the mutations and phenotypes. Whole exome sequencing can achieve higher sequence
depth with less raw sequence and lower cost than whole genome sequencing since
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exome is about 1 % of the genome size in humans. A key challenge for researches is to
distinguish between driver mutations that lead to cancer development and passenger
mutations, which are functionally neutral and do not contribute to tumorigenesis. A
common method for identifying driver mutations is to find genes, which are recurrently
mutated in large cancer samples. Initially, cancer genes such as p53, Myc, PTEN and
IDH1 were recurrently discovered suggesting their role as key driver genes, but ample
evidence demonstrates that pathways or subnetworks are better predictors because they
reduce the complexity and diversity of driver mutations to be identified [128].
In normal cells, CpG islands preceding gene promoters are generally unmethylated,
and tend to be transcriptionally active, while other individual CpG dinucleotides
throughout the genome tend to be methylated. However, in cancer cells, CpG islands
preceding tumor suppressor gene promoters are often hypermethylated, while CpG
methylation of oncogene promoter regions and retro-sequences (retrotransposons,
retrovirus) repeats is often decreased, which results in an aberrant pattern of gene ex-
pression compared to normal cells [129]. By contrast, hypomethylation of CpG dinucle-
otides in other parts of the genome leads to chromosome instability due to
mechanisms such as loss of imprinting and reactivation of transposable elements. Thus,
as a result of DNA methyltransferase (DNMTs) disruption, mitotic recombination and
chromosome rearrangement can be promoted by a defective methylation pattern,
which can ultimately end up in aneuploidy when the chromosomes fail to separate
properly during mitosis. Methodological progress for high coverage and single base
resolution profiling of the mammalian methylome in small numbers of cells through
NGS has enabled deep analysis between cancer and epigenetic dysregulation [130].
According to the landscape just described, the Memorial Sloan Kettering Cancer Center
has created a facility of PM called MSK-IMPACT, which routinely uses breakthrough
technologies such as genomic screening approach and hybridization capture-based next-
generation sequencing for solid tumor diagnostics [131]. A key question is what tumor se-
quencing might reveal; it is not yet clear whether cancer somatic alterations identified are
recurrently affecting specific genes and to what extend a treatment may rely on mutation
landscape description for a particular patient [127]. It has become clear that mutational
and copy-number status alone are not highly predictive of drug response, hence there is
an urgent need for improved in silico predictors of drug sensitivity [132]. In that respect,
transcriptome profiling is synonymous with what you see is what you get and offers a
benefit for the application of PM in real cases [133, 134].
Transcriptome profiling
High-throughput RNA sequencing has vastly expanded the scope of genomic investiga-
tions. Most BC patients treated with adjuvant chemotherapy do not get any tangible
survival benefit, yet are still exposed to the toxicity of the therapy. There is an urgent
need for: (i) a precision diagnosis that would be positively correlated with an efficient
therapeutics and (ii) predictive markers for patient’s response to chemotherapy being
positively correlated with clinical outcome expectation. Since the oncogenesis process
involves the dysregulation of several cellular pathways including cell cycle, growth, sur-
vival and apoptosis, high throughput transcriptome profiling provides a powerful tool
to identify suitable disease markers and to establish a BC prognosis.
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Microarray
Comprehensive gene expression profiling by microarrays enabled the study of thou-
sands of genes in tens of samples and various gene clusters were correlated with dis-
tinct tumor phenotypes suggesting that tumor grades are associated with distinct gene
expression signatures [135]. However, microarrays have two major shortcomings: They
are limited to known genes and they have limited sensitivity as well as dynamic range.
In addition, a number of clinical studies have often correlated alterations in the expres-
sion of individual genes with disease outcome according to contradicting results. Some
important claims about markers for diagnosis and prognosis have been unreliable and
only weakly reproducible or not reproducible at all and the process of development
seems slow and inefficient [136]. In fact, most of molecular predictors were generated
using a mix of molecularly heterogeneous tumors. Since oncogenic events are different
across molecular classes, optimal predictors should be set up in each molecular class.
Unfortunately, even under these conditions, comparisons of gene sets derived from
various studies show little overlap. This may be due to the different types of arrays
used, sample quality and defined parameters used for data interpretation. Oligonucleo-
tide arrays have an additional step of target RNA amplification via in vitro transcrip-
tion, leading to the loss of a linear relationship between the samples studied. In
addition, a second loss of linearity occurs during the detection of the hybridized cDNA.
Microarray technology is susceptible to a number of potential errors not just at the
time of sampling, preprocessing and processing, but also at the time of data calibration
and analysis [135]. Comparisons of gene lists derived from genetic assays that have
been currently licensed for commercial use show limited or zero overlap between sig-
natures. The reasons for this disparity have been attributed to differences in the groups
of patients analyzed (ER status, tumor grade, stage, etc.), in sample preparation (bulk,
microdissected, etc.), in microarray platforms (high or low coverage of the human gen-
ome) and in the statistical methods used (supervised or unsupervised methods, gene se-
lection, construction of the classifiers, etc.). The lack of standardization in the setup
methodology of these testes has resulted in poor prognostic reproducibility [137, 138].
RNA-seq
The RNA content and RNA make-up of a cell depend very much on its developmental
stage and on its type. Embryonic SCs express fewer genes with an average of 22,000
mRNA molecules per cell compared to embryonic fibroblasts whose average number of
mRNA molecules is 505,000 per cell, suggesting that the latter cell type contained a
~20-fold more mRNA. The same difference is observed for ribosomal RNA (small sub-
unit), suggesting that embryonic SCs contain overall less RNA than embryonic fibro-
blasts, on the order of a 5.5-fold difference in total RNA [139]. A typical mammalian
cell contains 10–30 pg total RNA, with 10 pg corresponding to ~103,000 mRNA mole-
cules, on average. The majority of RNA molecules are tRNAs and rRNAs. mRNA ac-
counts for only 1–5 % of the total cellular RNA although the actual amount depends
on the cell type and physiological state. Approximately 360,000 mRNA molecules are
present in a single mammalian cell, and are made up of approximately 12,000 different
transcripts with a typical length of around 2 kb. Some mRNAs comprise 3 % of the
mRNA pool whereas others account for less than 0.1 %. These rare or low-abundance
mRNAs may have a copy number of only 5–15 molecules per cell [140].
Carels et al. Theoretical Biology and Medical Modelling  (2016) 13:7 Page 24 of 46
These considerations are important when comparing transcriptomes of different cell
types and show the need for a normalization not only for read number according to cod-
ing sequence size [141], but also for differences of mRNA per experiment that result from
variation of mRNA content per cell type or sequencing coverage [142]. Typically, the tran-
scriptome of a cell line or tumor sample is sequenced, normalized and compared to a
sample of normal tissue by subtraction of relative read count per gene. Genes with a sta-
tistically significant expression level at P < 0.001 are considered up-regulated or down-
regulated according to the normal sample used as a control [133] (Fig. 4). RNA-seq gives
a measure of gene expression that is much more precise and reproducible than that ob-
tained by microarrays and in agreement with qRT-PCR, which allows the extension of
basic research (RNA-seq) to clinical application by qRT-PCR or Ampliseq. Ampliseq re-
fers to NGS sequencing of amplicons from a DNA or mRNA sample [143]; this method
allows the measure of relative expression levels of a predetermined pool of chosen genes
(typically ~400) with the aim of obtaining a sample signature.
Micro RNA (miRNA) constitutes another layer of gene regulation (that is referred to as
the regulome together with transcription factors) whose evaluation is also accessible
through RNA sequencing; the function of these small non-coding RNA molecules (~22
nucleotides) is the post-transcriptional regulation of gene expression by mRNA silencing
[144]. The expression of miRNA is highly specific of tissues and developmental stages,
and the functions of miRNAs have been appreciated in various fundamental biological
processes such as cell death, cell proliferation, and stem cell division. miRNAs can act as
oncogenes and tumor suppressor genes. The overall miRNA expression tends to be down
regulated and miRNA level is lower in poorly differentiated breast tumors with respect to
well differentiated ones. Twenty-nine miRNAs were reported to be differentially expressed
in BC versus normal tissues as well as miR-143, miR-145, miR-16, and let-7a-1 in MCF-7
and T47-D cell lines (see refs in [145]). Mechanisms for aberrant miRNAs expression
may occur because of genomic alterations such as insertion or deletion since 72.8 % of
miRNA genes were shown to be located in regions that exhibit DNA copy number abnor-
malities in BC [146]. In addition to copy number alteration, aberrant DNA methylation
and demethylation as well as chromatin remodeling may also account for the frequent
miRNA dysregulation in BC. miRNAs are intertwined with cellular pathways, and regu-
lated by oncoproteins and tumor suppressors such as ErbB2, Akt, NF-κB, Myc, Ras,
pTEN, p53, and Rb. Incorporation of miRNA regulation into current models of molecular
cancer pathogenesis is essential to achieve a complete understanding of BC development.
miRNAs with pro-proliferative and anti-apoptotic activity would likely promote oncogen-
esis and thus may be over-expressed in cancer cells. Likewise, miRNAs with anti-
proliferative and pro-apoptotic activity are likely to function as tumor suppressor genes
and thus may be under-expressed in cancer cells [147].
Proteome profiling
Proteomes carry biological information that is not accessible by genomics or tran-
scriptomics. In humans, the proteome size is 19,629 as annotated in Swiss-Prot; signa-
tures for ~80 % were detected by mass-spectrometry (https://www.proteomicsdb.org/).
Proteome coverage rapidly saturates at approximately 16,000 – 17,000 proteins, which
is similar to transcriptome coverage obtained by RNA-seq, and includes a core
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proteome of 10,000 – 12,000 ubiquitously expressed proteins. When comparing mes-
senger RNA-seq and proteins, clear correlations are observed in all tissues, but the cor-
relation coefficients are moderate and somewhat poorer than those obtained for cell
lines, which can be expected from the fact that tissues generally comprise a mixture of
cell types including connective tissue and blood. Both mRNA and protein levels vary
greatly among tissues, but the ratio of protein and mRNA levels is remarkably con-
served between tissues for any given protein suggesting that the actual amount of pro-
tein in a given cell is primarily controlled by regulating mRNA levels. Knowing the
protein/mRNA ratio for every protein and transcript, it is possible to predict protein
abundance in any given tissue with good accuracy from the measured mRNA abun-
dance [148].
Considering the proteome fraction dedicated to signaling, it has been shown that at
least three-fourths of the proteome can be phosphorylated. In eukaryotes, phosphoryl-
ation occurs almost exclusively on Ser (84.1 %), Thr (15.5 %), and Tyr (0.4 %) residues,
which represent approximately 17 % of the total amino acids in an average human
Fig. 4 Sub-network of differentially expressed genes obtained by subtracting the RNA-seq of MCF10A
(control) from that of MDA-MB-231 (Triple-Negative), represented in a circular layout. Nodes represent genes
while links represent interaction between genes. Size nodes indicate connectivity and color represent an
expression pattern between malignant versus non-malignant breast cell line (green: down-regulated, red:
up-regulated). Gephi was used for network visualization (from [131])
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protein with most Tyr kinases only activated under specific circumstances and usually
stringently negatively regulated. The vast majority of phosphorylation events together
use less than 20 % of cellular ATP consumed in protein phosphorylation [149].
The proteomic landscape of TN cell lines has shown that driver mutations occur fre-
quently in regulatory proteins such as protein kinases, E3 ubiquitin ligases, and tran-
scription factors, which alter the physiology of the cell by modulating the abundance or
activity of other proteins revealing 233 hub proteins, each associated with three or
more cancer census genes and “cell cycle” the only significantly enriched gene ontology
(GO) term among hub proteins [150].
A full understanding of genotype-phenotype relationships in human BC requires the
description of how protein interactome network is perturbed by genome alterations. In
molecular biology, an interactome is the whole set of molecular interactions in a par-
ticular cell. It refers specifically to physical interactions among proteins, also known as
protein-protein interactions, i.e., physical contacts established between two or more
proteins as a result of biochemical events and/or biophysical forces. Here, we more par-
ticularly refer to transient interactions among proteins in the context of signaling net-
works, i.e., the protein pathways that connect protein receptors on the cell surface with
transcription factors that (up- or down-) regulate gene expression. Evidence of protein-
protein interactions represented by binary pairs can be obtained by mammalian
protein-protein interaction trap [151], yeast two-hybrid (Y2H) assays [152] or supported
by multiple pieces of evidence from the literature [153]. A systematic literature bias in-
herent to binary PPIs is that some genes are described in hundreds of publications
while others have been mentioned only in a few due to the tendency to expand know-
ledge from already connected proteins as a consequence of socio-economic constraints.
As expected from a limitation of the Y2H, the interactome obtained with this assay is
depleted of interactions among proteins containing predicted transmembrane helices.
Today, the human interactome lists interactions for ~17.000 proteins.
Network modeling
A key challenge is to understand the structure and dynamics of intracellular interac-
tions that contribute to the structure and function of a living cell. The functioning of a
cell has three layers of articulation, i.e., signaling, metabolism and transcription.
Roughly speaking, signaling transmits environmental signals from membrane receptors
to the nucleus through a complex protein network that ends up with transcription fac-
tors activating a layer of transcription regulation involving positive and negative feed-
back loops that regulate gene expression. In addition to signaling and transcription
feedback, gene expression also results in metabolism maintenance through enzyme fos-
tering. These three cell activity layers form a complex network of protein-protein (PPI),
protein-DNA/RNA, and protein-ligand interactions. Mathematically, network interac-
tions are generally displayed by either a directed or undirected graph G = (V, E) with
vertex (node) and edge sets V and E, respectively. An edge appears in the graph if there
is a known interaction of the two partners, for example two interacting proteins in a
cell, either by direct binding or by enzymatic catalysis. A node is referred to as a node
of degree k if it is connected to other nodes by k edges. The connectivity level (or rate)
of a network characterizes the average number of interactions (edges) per node. When,
a node has a number of interactions (connections or edges) significantly larger than the
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average, it is called a hub. Top-5 (or 10, or more) refers to the 5 (or 10) best items in a
list for a given feature under consideration.
The connectivity of a node measures its local contribution to network complexity
and can be reported in terms of statistical mechanics through the concept of entropy.
In thermodynamics, entropy (usually denoted by symbol S and referred to as the Boltz-
mann entropy) is a measure of the number of specific ways in which a thermodynamic
system may be internally rearranged between its microstates, which is commonly
understood as a measure of disorder. In statistical mechanics Boltzmann’s equation re-
lates the entropy S of an ideal gas to the quantity W, which is the number of micro-
states corresponding to a given macrostate, i.e.
S ¼ kB lnW ð1Þ
where kB is the Boltzmann constant equal to 1.38065 × 10
−23 J/K. For thermodynamic
systems where microstates of the system may not have equal probabilities, the appro-




Here, the subscript i runs over all microstates and Eq. 2 reduces to Eq. 1 if the prob-
abilities pi are all equal (to 1/W). In information theory, entropy (the so-called Shannon
entropy) is the negative of the expected value of the information contained in a mes-
sage received. Mathematically speaking the Shannon entropy, H, of a discrete random
variable X is a measure of the amount of uncertainty associated with the value of X
when only its distribution is known. So, for example, if the distribution associated with
a random variable is constant (i.e. equal to some known value with probability 1), then
entropy is minimal and equal to 0.




p kð Þ lnp kð Þ ð3Þ
where p(k) represents a probability distribution on the nodes of the network, p(k) = Vk/
V with Vk the number of nodes with degree k and V is the total number of nodes in
the network.
Mutual information (MI) is another degree-entropy derived measure that is exten-
sively used for network characterization (Eq. 4). It provides a natural generalization of
the correlation since it measures a non-linear dependency and it is able to deal with
thousands of variables (genes) on a small sample number. MI measures the dependency
between two variables. For discrete variables X and Y, MI is defined as:
IðX;Y Þ ¼ −
X
x∈X;y∈Y
pðx; yÞlog pðx; yÞ
pðxÞpðyÞ ð4Þ
where p(x, y) is the joint probability of x in X and y in Y. In terms of degree-entropy,
MI can also be defined as Eq. 5:
I Χ;Yð Þ ¼ H Χð Þ þ H Yð Þ‐H Χ;Yð Þ ð5Þ
Network entropy provides a quantitative measure of the differentiated state of a cell
[154]. It has been shown that: (i) network entropy is a discriminator of pluripotent and
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non-pluripotent cell-types, (ii) it can further discriminate cellular states of varying de-
grees of multipotency within distinct lineages, (iii) it provides a more robust and gen-
eral measure of a cell’s position in the global differentiation hierarchy than gene
expression signatures, and (iv) it predicts a higher cellular heterogeneity in cancer stem
cells compared to ordinary cancer cells. The higher entropy of pluripotent SCs com-
pared to normal differentiated cells [132], has been seen to be due to the necessity of
SCs to maintain the option of initiating the activation of a wide number of different sig-
naling pathways associated with commitment to diverse cell fates [155]. Interestingly,
network entropy of tumors as been also correlated with their aggressiveness [154, 156]
establishing a correlation between malignant cell line differentiation and aggressiveness,
which is consistent with the positive relationship between cell adaptiveness and toti-
potency. In fact, metastatic BC is characterized by an increase in the randomness of the
local expression correlation patterns [157]. According to the observation that malignant
cells are engaged in a fight for survival, their largest entropy compared to normal cells
establishes a positive correlation with their survival success from a Darwinian perspec-
tive [158]. It has also been shown that drugs can be classified as either cytotoxic or
target-specific as well as ranked according to their likelihood of controlling a tumor
given its transcriptome profile using entropy as a measure [134].
The degree distribution of most biological networks can be represented by a power
law P(k) ~ k–γ, where γ is the degree exponent and “~” indicates the proportionality be-
tween both terms. The smaller the value of γ, the more important the role of the hubs
is in the network. For γ = 2, the network is characterized by a mixture of densely (hub)
and scarcely connected nodes without apparent structure. In this configuration, the lar-
gest hubs are connected (edges) with a large fraction of all nodes, which ensures fast
navigability of the whole network through only a few nodes or, in other words, a small
network diameter. For 2 > γ >3 (scale-free), the most connected hub is in contact with
only a small fraction of all nodes according to a hierarchical structures accompanied by
a decrease in network navigability and an increase in network diameter. By contrast,
for γ >3 the network structure in hub and non-hub nodes disappears and navigation
from one node of the network to another results in passing through a large node num-
ber, which increases further the network diameter and brings it closer to a random con-
figuration where nodes are connected on average through a similar edge number and
whose distribution follows a Poisson distribution [159].
Most biological networks show a scale-free topology. The anisotropic node distribu-
tion in a scale-free network can be represented by several measures including the clus-
tering coefficient and centrality [160]. The clustering coefficient can be written as Ci =
2ni/k(k–1), where ni is the number of edges connecting the ki neighbours of node i to
each other. Ci gives the number of triangles that go through node i, whereas ki(ki –1)/2
is the total number of triangles that could pass through node i, should all of node i’s
neighbors be connected to each other. The average clustering coefficient < C > charac-
terizes the overall tendency of nodes to form clusters or groups while the average clus-
tering coefficient C(k) of all nodes with k edges is a measure of the network’s structure.
The average degree < k>, average path length < λ > and average clustering coefficient <
C > depend on the number of nodes and edges (V and E) in the network. By contrast,
the P(k) and C(k) functions are independent of the network’s size and capture generic
features, which allows them to be used for network classification [159].
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Centrality identifies the nodes that are the most important ones in terms of graph con-
nectivity [161]. There are several measures of centrality, but the prominent one is
betweenness-centrality (Eq. 6). Given a network graph G(E,V) consisting of nodes V and
edges E, the betweenness-centrality CB is a measure of the centrality of a node, v. Typic-
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where σ(s,t) is the number of shortest paths between two nodes (s,t) and σ(s,t|v) is the
number of those paths passing through nodes other than v. Here, the biological system
studied represents the interactome structure for a cell, i.e., the number of edges (inter-
actions with neighbor proteins) per node (proteins in the network). The probability dis-
tribution of the events (the probability of a given number of edges per node), coupled
with the information amount (the probability of a given number of edges for the node
considered multiplied by its base 2 logarithm) of every event (node), forms a random
variable whose average (also termed expectation value) is the average amount of infor-
mation. Its inverse is the network entropy generated by this distribution.
Cellular networks are generally scale-free or a mixture of scale-free and hierarchical
modularity as is the case of transcription regulatory network where the distribution
that captures the number of different genes interacting with a transcription factor fol-
lows a power law, while the number of different transcription factors that interact with
a given gene is best approximated by an exponential function [162]. In any case, cellu-
lar networks have a disproportionate number of highly connected nodes with the con-
sequence that their path length is ultra small [163], which indicates that local
perturbations in metabolite concentrations could reach the whole network very quickly.
Interestingly, in protein interaction networks, highly connected nodes (hubs) avoid
linking directly to each other and instead connect to proteins with only a few interac-
tions, which warrant the disassortativity required for network stability and fast commu-
nication between clusters (modules) where proteins associated to a same function are
thought to interact [164]. Modules can be detected through their clustering coefficient
C(k) due to the higher local triangle density connecting cluster nodes. This indicates
that nodes with only a few edges have a high C(k) and belong to highly interconnected
small modules. By contrast, the highly connected hubs have a low C(k). Module identi-
fication is complicated by the fact that scale-free property and modularity are conflict-
ing. By definition, modularity implies the existence of clear boundaries in the system.
However, in a scale-free network hubs are in contact with a high fraction of nodes,
which makes the existence of relatively isolated modules unlikely. Clustering and hubs
coexist, which indicates that topological modules are not independent, but combine to
form a hierarchical network [165]. In addition, modules are not isolated from each
other; they interact and frequently overlap, which makes search for clear module
boundaries nonsense and suggests that looking for hierarchical relationship between
modules of different sizes is indeed the method of choice [166].
A fundamental property of a scale-free network is its high robustness level to random
perturbation (node elimination), but strong vulnerability to hub elimination that makes
them collapse quickly under specific attack. This property is due to the power law
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properties of scale-free networks where nodes with a low connection rate are much
more numerous than hubs, which makes hub inactivation much less likely to occur
upon random selection. When hub nodes are eliminated, the diameter of the scale-free
network increases rapidly, doubling its original value if 5 % of the nodes are removed
and leading to the fragmentation of module interconnections [167].
Gene regulatory networks
Gene regulatory networks (GRN) are statistical networks inferred from gene expression
data according to the hypothesis that co-expressed genes encode interacting proteins.
GRN reconstruction is a daunting task due to the fact that mRNA concentrations pro-
vide only indirect information about interactions occurring between genes and their
gene products. Gene expression data are multidimensional and nonlinear due to the
coordination of DNA transcription, mRNA translation, protein processing as well as
mRNAs and protein turnover [168, 169].
A variety of approaches have been proposed to infer GRNs such as discrete models of
Boolean networks and Bayesian networks, differential equations, regression methods
and linear programming, and MI (see refs in [170]). MI has been a successful frame-
work for additional methodology refinements. In general, these approaches start by
computing the pairwise MIs between all possible pairs of genes, resulting in a MI
matrix. The MI matrix is then manipulated to identify the regulatory relationships.
However, such a matrix contains a huge amount of information corresponding to genes
that do not show any significant link with the experimental case. This problem has
been typically addressed by pairwise statistical comparison using t-testing, for instance,
in order to eliminate edges scoring below a significance level threshold and to keep
edges between gene pairs that maximize all combinations [169, 170]. Bootstrapping has
also been applied to optimize GRN tuning [169].
The relative strengths and drawbacks of computational and statistical approaches to
infer GRN remain poorly understood, largely because comparative analyses usually
consider only small subsets of methods, use only synthetic data, and/or fail to adopt a
common measure of inference quality. Large differences of predictive accuracy exist in
the method used to infer GRNs that depend on network size, topology, experiment
type, and parameter settings [171]. However, the methodology is worthwhile since it
may cluster genes that are potentially acting in a same functional module and ranks
modules according to their relative level of expression, which adds another layer of in-
formation when interpreting results in the light of PPI networks inferred from experi-
mental data [133, 134].
Protein-protein interactome
Boolean networks are a promising framework for modeling signaling networks [172].
Instead of providing quantitatively precise dynamical trajectories taken by complex net-
works, this class of discrete systems qualitatively predicts the sequences of states
accessed by these networks along their temporal evolution through binary states. This
is especially convenient for signaling and regulatory circuits where activation (1) and
inhibition (0) are the basic states. According to this framework, every protein evaluates
the present stimulus on all its inputs. If the overall stimulus it receives at time t
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overcomes its activation threshold, the protein is activated, or stays active if it was
already active; otherwise, it turns inactive or stays inactive. The dynamics of the net-
work proceeds in discrete time steps through the simultaneous update of the states of
its nodes and flows in this state space towards attractors [173, 174]. Such attractors are
particular subsets of states or a single network configuration that correspond to specific
protein activation patterns and can be interpreted as distinct cell phenotypes. In the
model of Fumiã and Martins [172], the repertoire of cell behaviors (attractors) is deter-
mined unambiguously by the cell microenvironment and among the 62 attractors, 47
(87.4 %) correspond to apoptotic, 3 (3.1 %) to proliferative and 12 (9.5 %) to quiescent
phenotypes. Interestingly, bistability was observed upon DNA damage introduction
under a scenario of normal oxygenation and nutrient supply, but mitogenic signaling.
Under such circumstances, around 99.35 % of the compatible initial states were
attracted to the apoptotic phenotype, while a very small fraction (0.65 %) of them
reached the proliferative phenotype. The other significant outcome of this modeling ap-
proach was that the monotherapies tested were ineffective to simultaneously reverse all
the malignant hallmarks and seem to be additive in their effects with the consequence
that a drug cocktail is necessary for cancer control or eradication.
Relationship between disease and protein networks
The complete list of disease genes or diseasome with a phenotype effect described
allowed the design of a graph where each known disorder/disease is associated to a set
of genes. This experiment has shown significant functional association between cellular
network modules and disorder in ~300 interactions. It was concluded that in agree-
ment with the GRN hypothesis, genes that contribute to a common disorder: (i) show
an increased tendency for their products to interact with each other through protein-
protein interactions, (ii) have a tendency to be expressed together in specific tissues,
(iii) tend to display high co-expression levels, (iv) exhibit synchronized expression as a
group, and (v) tend to share GO terms. Together, these correlations support the hy-
pothesis of a global functional relatedness for disease genes and their products and
offer a network-based model for the diseasome. According to these conclusions, a dis-
order then represents the perturbation or breakdown of a specific functional module
caused by variation in one or more of the components producing recognizable develop-
mental and/or physiological abnormalities [126]. The facts that: (i) the vast majority of
disease genes (~80 %) were concluded to be merely nonessential to the cell; (ii) the ex-
pression pattern of nonessential disease genes is decoupled from the overall expression
pattern of all other genes, whereas essential genes have a tendency to be coupled to the
rest of the cell and contribute most to the network entropy [132]; and (iii) nonessential
disease genes tend to occupy functionally peripheral and topologically neutral positions
in the cellular network [126] confirm that diseases genes are activated in the context of
metabolism rewiring under network dysregulation and suggest that their specific con-
trol would not impair the normal cell functioning. However, in the case of cancer cells
the few dysregulated genes encoding hubs may play a central role in the navigability of
rewired pathways and their deactivation is expected to be critical for the disease control
by disconnecting disease modules without impairing the functioning of normal cells
[134]. By extension, disease hub inactivation is expected to break down attractors that
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are essential for cancer progression and to bring cellular activity in alternative attrac-
tors eventually ending up into apoptosis.
Characterization of protein targets
In an in silico evaluation, [134] classified drugs involved in cancer therapy [175] could
be separated into two general classes, i.e., (i) agents that target specific receptors such
as those including angiogenesis, cell cycle, microtubule/cytoskeleton, EGFR/FGFR/
HER2/IGFR signaling pathways, Ras-Raf-MEK-MAPK-ERK pathway, mTOR pathway,
PI3K-AKT pathway, HDAC epigenetic agents, and HSP90s; and (ii) broad cytotoxic
chemotherapeutics including nucleotide synthesis, metabolism, DNA cross-linker and
multiple targets, defined as various. They found a tendency in malignant cell lines to be
more sensitive, on the average, to target-specific drugs than to broadly cytotoxic ones.
Cytotoxic drugs were performing poorly, on average, since their associated –
log10(GI50) was never larger than 5.3, on average, which is considered as a rule of
thumb by the state of the art of drug development as the minimal half cell growth in-
hibition (GI50) (the concentration of a drug that is needed to inhibit 50 % of cell prolif-
eration) necessary at a 10 μM concentration to consider a candidate molecule as a
potential lead compound. By contrast, target specific drugs were showing, on the aver-
age, a –log10(GI50) larger than the 5.3 threshold. When comparing the entropy per
node of the total protein network of a cell line to its value of –log10(GI50) for different
drugs, a clear negative correlation (r = −0.859) could be found, on average, for target-
specific drugs. The negative correlation was especially convincing when considering lu-
minal (r = −0.923) and TN cells (r = −0.725) separately. Given that target inactivation by
specific drugs appeared as a more productive strategy than therapies based on cytotoxic
compounds, Carels et al. [134] listed the top-5 most connected proteins encoded by
up-regulated genes according to a p-value of 0.1 %. The subtraction of the entropy con-
tribution of each top-5 from the total protein network entropy corresponding to the
cell line under consideration gave a net entropy corresponding to that network, which
meant the predicted benefit due to the target inactivation. By interpolation with the or-
thogonal regression line through average network entropies of TN, luminal, and control
cell lines, on one hand, and patient 5-year survival [176], on the other hand, the inacti-
vation of most top-5 targets brought the entropy back to values close to or below the
entropy of the control, which meant that top-5 targets are worth considering for drug
development since they potentially offer a complete 5-year survival of the patient popu-
lation under consideration. However, the exact hub number that should be ideally deac-
tivated has not been investigated.
Let us also note here that the existence of an interacting sub-network between down-
and up-regulated genes indicates that the differentially expressed genes, in addition to
being induced by specific cancer pathways, are interacting with each other apparently
in a compensatory way [133], which further confirms the notion that oncogenesis and
tumoral progression require multiple and crosstalk signaling and that a therapy driven
against up-regulated genes may also affect down-regulated ones.
The result just described has shed an important light on the outcomes of therapies
based on drug cocktails, which are predicted to increase the benefit expected from
chemotherapy compared to treatments based on single drugs. Thus, a method is
needed that enables the malignant population to be completely eliminated within a
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desired time-frame, negating the possibility of recurrence and promoting drug resist-
ance. The difficulty of eradicating a mass of malignant cells is due to the nature of reac-
tion kinetics that governs the interaction of these cells with the therapeutic agents
administered. Therapeutic agents cause an exponential decay of the malignant cell
population leaving a finite number of cells at the asymptotic extremity of the time of
drug treatment curve as a natural consequence of the asymptotic curve that only comes
into contact with the horizontal axis at a theoretically infinite time of treatment. If this
situation is not taken into consideration, the necessary finite time of treatment leaves a
small number of residual malignant cells that later lead to secondary malignances. A
solution that has been successfully implemented by Kapoor et al. [177] has been to
consider a tumor population at a value larger than it actually is, which causes a shift to
increase the treatment dose or equivalently that forces the asymptotical exponential de-
creasing of malignant cell decay to cut the horizontal line at a finite time interval from
the treatment initiation rather than at an infinite time. For this process to be efficient,
all therapeutic and cell parameters must be carefully taken into account in a nonlinear
model described by differential equations. The input dose of therapeutic agents was cal-
culated according to a predefined time at which malignant cells are planned to be ex-
tinct. This calculation was made through a reverse engineering process using control
strategy whose optimality has been solved by the classical method of Lagrange multi-
pliers. The therapeutic treatment included one chemotherapeutic (cytotoxic) and two
immunotherapeutic (Interleukin and Cytotoxic T-lymphocyte) agents. Such a process
could be optimized to take several target-specific chemotherapeutic agents in addition
to the immunotherapeutic ones. This operation would have the effect to relax the
physiological constraints into which the system is forced to operate to warrant patient
safety due to the inherent toxicity of chemotherapeutic cytotoxic agents. By integrating
Loewe additivity and Bliss independence [178, 179], such a strategy would allow the full
modeling of oncotherapeutic PM from molecular target to drug posology and to fully
investigate the nature of their relationships with respect to the signaling network
components.
Challenges of precision therapy
Today, the concept of PM is defined by using terms such as the customization of med-
ical treatment to an individual’s genetic profile [180]. Although an attempt to support a
unique definition of PM has been published, various competing definitions using some-
what different nomenclature (e.g. “stratified\individualized” instead of personalized)
persist in the literature. But all definitions share in common some form of genetic test-
ing to identify and target specific patient profiles in order to deliver “the right drug to
the right patient” and to maximize treatment effectiveness and safety [181–183].
The fast growth of genetic knowledge has allowed the shift from individual gene test-
ing (genetics) to multiple gene evaluation (genomics). The enthusiasm for personalized
medicine in oncology has been fueled by success stories of targeted therapies in a var-
iety of tumors based on their molecular profiles [184, 185].
Pharmacogenetics is the study of inherited genetic differences in drug metabolic
pathways that can affect the response of individual patients to drugs. By definition, a
pharmacogenetic interaction implies that a causal genetic factor has differential effects
on outcomes in treated versus untreated patients. The prior assumption is that patients
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should not show any positive effects without therapy application. However, tumor het-
erogeneity impacts on treatment regimen as combinatorial therapies are required to
target different cancer cells and it makes difficult to interpret the treatment outcome.
According to the World Health Organization (WHO), there are at least 18 different
histological subtypes of BC, and a variety of grading and corresponding diagnostic
schemes [186–188].
Although the challenges inherent to the integration of cancer, pharmacogenetics and
targeted therapies into clinical practice should require evidence of benefit to the pa-
tients, an additional important parameter to consider is the cost-effectiveness for the
healthcare system [188]. In this context, the PM management of cancer implies the pre-
scription of target-specific therapeutics that is best suited for individual patients ac-
cording to the type of tumor they develop. The purpose of PM strategy is to increase
the efficacy of anticancer agents and to avoid toxic side effects as much as possible,
which are a critical issue in clinical oncology [189]. One may consider at first glance
that personal therapies can only be more expensive than standard ones, however, such
a cursory assessment does not take into account the cost of administration of an inef-
fective treatment and the costs associated with the loss of life in terms of societal
issues.
Regarding treatment costs, patients may have health care access provided through na-
tionally funded programs according to their geographic place of residence, but the allo-
cated resources may vary widely. Access to newer therapies and their accompanying
diagnostics is often restricted as prices often exceed the thresholds used to approve
new treatments. Medical insurance companies also place restrictions on diagnostic
tools for cutting-edge treatments that are not supported by third-party payers. Health
cost strategies vary worldwide. However, they all have a similar background of cost-
driven logic. In Brazil, for instance, patients may have recourse to justice to benefit
from a breakthrough treatment not normally covered by the federal health system. Ac-
cess imbalances can only increase as the identification of novel targets and treatments
continues. Organizations such as the Health Economic Policy and Reimbursement
Committee within the European Personalised Medicine Association and the Persona-
lised Medicine coalition have provided recommendations to address the delivery of PM
across Europe and produced working documents that summarize the need to re-
evaluate existing assessment and payment systems. A key challenge is to provide evi-
dences to support the notion that PM can increase benefits to patients while lowering
overall costs. On the other hand, while the cost of implementing PM may be high, one
could also ask what would be the cost of not pursuing it [5].
Over the last several years, FDA (http://www.fda.gov/Drugs/InformationOnDrugs/
ApprovedDrugs/default.htm) has accelerated the rate of anticancer drug approval, but
only a small fraction of these new drugs found their way to a wide clinical use. FDA
currently includes 155 pharmacogenetic labels, and 52 are related to oncology. Actually,
nearly half of the recent cancer drug approvals (48 %) are first class, i.e., interesting
drugs that use a novel mechanism of action. The better understanding of disease mech-
anisms and human biology has made possible to develop more effective therapeutic ap-
proaches driven by genomics and pos-genomics targets [189, 190].
Pharmacogenomic research can have an impact on how the pharmaceutical industry
develops cancer drugs by identifying the genes and their isoforms involved in the
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interaction between a drug and the body. Bioinformatics, cheminformatics and pathway
analysis developed numerous resources for pathway and network analysis, such as Bio-
carta, Ingenuity, KEGG and PharmaGKB, which are being used to speed up the discov-
ery of suitable gene targets, lead compounds (potential drugs) and new molecular
targets by high-throughput drug screens (HTS). Additionally, the discovery of pharma-
cogenomic variants improves the design of clinical trials and optimizes the drug transit
through the pharmaceutical pipeline [188, 190, 191].
Molecular and physiological effects of drugs in precision therapies
Physicians prescribe medications based on clinical evaluation or on evidence from clin-
ical trials. To select a drug and a dosage, physicians take care of clinical factors such as
weight, gender or organ function. The individual variation that may affect drug selec-
tion or dosage, such as genetic factors, is only rarely taken into consideration [188].
In one very simple scenario, a drug may act as an agonist or an antagonist for a re-
ceptor, composed of one or more proteins. At a molecular level, the metabolite can
bind to the protein’s active site, which can be a ligand-binding site, a conformation-
altering site or a catalytic site. Thus, the effect of a drug can then be propagated
through biochemical pathways to produce cellular and systemic physiological effects.
Drug metabolism can lead to the conversion of a precursor metabolite into an active
drug or to the breakdown of an active into an inactive form suitable for excretion. In
some cases, structurally similar molecules (e.g. a drug that is similar to a protein’s nat-
ural ligand) can bind and affect the same region of the protein and produce pharmaco-
logical effect. The absorption and distribution as well as inter-individual metabolic
variation can often be explained by genetic factors [188, 192].
The most famous drug-metabolizing proteins are members of the cytochrome P450
family, which are involved in the phase I metabolism of the majority of known drugs.
Polymorphisms in these genes have been involved in human drug response variation
and can affect up to 25 % of all therapies [193–195].
As outlined above, tamoxifen is an anti-estrogenic drug used as adjuvant in the treat-
ment of BC that reduces substantially the mortality due to malignant cells with estro-
gen receptor-α (Rα). This therapy has been the main focus of a large number of studies
with emphasis on germline genotyping as a tool to improve guide treatment [196, 197].
The formation of two major primary metabolites of tamoxifen, N-desmethyl-tamoxifen
and 4-hydroxy-tamoxifen, is catalyzed by CYP3A4\5 and CYP2D6, respectively. The
second metabolite 4-hydroxy-N-desmethyltamoxifen (endoxifen) is genetated from N-
desmethyl-tamoxifen by CYP2D6, and 4-hydroxy-tamoxifen substantially less by
CYP3A4\5 [198–200]. The endoxifen and 4-hydroxy-tamoxifen are potent anti-
estrogenic metabolites with a higher suppression rate of cell proliferation compared to
tamoxifen, which brings out key roles of CYP2D6 and CYP3A4\5 in tamoxifen bioacti-
vation [199]. FDA recommends CYP2D6 genotyping upon tamoxifen administration in
postmenopausal and premenopausal women [197, 201] because of variations in inter-
individual response due to genetic polymorphisms. For instance, different pharmacoki-
netic and pharmacodynamic effects were observed for various polymorphisms in the
CYP encoding genes such as CYP2B6, CYP2C9, CYP2C19 and CYP3A4\5 [197]. For
CYP2D6, there is a clear genetic effect partially explaining the inter-individual
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variability in endoxifen plasma concentration. Although the relationship between gen-
etic polymorphisms and tamoxifen pharmacokinetics or pharmacodynamics is well
understood, the variability in plasma concentration implies genotyping for tamoxifen’s
clinical applicability. Different factors can contribute to the observed inter-study het-
erogeneity, such as differences in the quantification of tamoxifen and its metabolites,
co-medications, administered dose, time on treatment, compliance, genotype compari-
son, tissues used for genotyping, deviation from the Hardy-Weinberg equilibrium, spec-
ifications of survival outcome, statistical power, methodology, and experimental design.
In addition, a large number of studies are biased in the polymorphisms that are taken
into account, which leads to potential phenotype misclassifications [197, 202].
PM is a fascinating issue however the clinical results have not been as encouraging as
expected so far. This is particularly true in oncology where PM was expected to be the
major field of application and where targeted therapies have not yet been able to re-
place classical chemotherapy [203, 204].
In general, target prioritization is a major issue and the discovery and development of
target-specific therapies is still the main bottleneck. A major challenge of PM with tar-
get- specific drugs is that most responses are still transient, and tumors acquire drug
resistance through genetic and non-genetic mechanisms.
Genomic and post-genomic era advances may increasingly provide assistance in difficult
clinical decisions, such as those involved in BC management. The recent high-throughput
technologies will facilitate pharmacogenomic progress and provide novel druggable mole-
cules as well as support the design of future strategies aimed at BC control. Thus, sub-
stantial research investments are still needed to identify when and for whom genomic
testing will be most beneficial for improved health and better oncology outcomes.
Engineering precision therapies
The underlying goal of improving systemic treatments of BC is to evolve from a shot-
gun approach of treating every patient with relatively non-specific cytotoxic chemother-
apy or hormonal therapy to a rational design in which patients are treated with
therapies aimed at specific molecular targets. As a matter of fact, a significant propor-
tion of BC patients are being over-treated: many patients are likely cured by locoregio-
nal therapy alone, but are enduring the side effects of unnecessary additional systemic
therapies [205]. Predictors of prognosis would decrease acute and latent toxic effects
and reduce treatment-associated costs. Because complex gene interactions control
tumor phenotypes, traditional techniques focusing on a single or few genes had only
limited success in the control of cancer disease and its prognosis. The identification of
BC molecular subtypes and the development of prognostic as well as predictive mo-
lecular signatures through gene expression profiling have resulted in a better appreci-
ation of the biological heterogeneity of BC [135].
In BC, genomic aberrations such as abnormal DNA copy number and their derived
prognostic have not advanced much except for HER2; much less is understood about
somatic mutations and therapy response according to survival expectation. By contrast
to microarrays where expression level or copy number can only be reported for the
pre-determined probe sequences tested, an added benefit of NGS is that it operates on
the whole-genome scale where a complete representation of the population of DNA or
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RNA molecules in a sample can be queried simultaneously, which has prompted the
Sweden Cancerome Analysis Network – Breast (SCAN-B) to sequence over 3,000
breast tumors to date [205]. The comparison of transcriptome profiling from malignant
cell, neighboring stroma cells, and healthy cells potentially allows the identification of
key protein targets involved in the malignant pathway rewiring [133]. The progressive
phenotype drift of malignant cells is a complicating factor, which promotes tumor cell
heterogeneity. However, it seems that key protein hubs are globally conserved in a
tumor cell population, which makes sense according to the concept of common ances-
tor. If all malignant cells of a solid tumor derive from the same BCSC common ances-
tor that was successful in its pathway rewiring strategy, descendant cells should have
kept such strategy even after adding new mutations. According to this notion, one may
expect that a global sequencing of a heterogeneous cell population should keep detect-
able the common denominator of overexpressed genes since they should be up-
regulated in most cells. By contrast, up-regulated genes from new mutations may not
be detected as a consequence of averaging expression data by sequencing cell lines
whose gene expression may be eventually in conflict. However, the astonishing progress
of laser capture microdissection (LCM) is expected to improve the management of
tumor heterogeneity. By combining LCM and linear amplification, it is already possible
to draw a RNA-seq from only 1 ng, which provides a powerful tool for transcriptome
analyses in the context of tumor heterogeneity [206].
Due to the advances achieved by basic research, it has become clear that even if the
mutation space is very large at the genome level, the number of possible dysregulated
pathways leading to cancer is much smaller, which inevitably implies phenotypic redun-
dancy at the level of protein hub targets as they can be inferred through RNA-seq
[133]. Consequently, the number of rewiring transformations from a dysregulated path-
way to another must be even smaller. The considerations above suggest that post-
treatment liquid biopsy should permit in the near future to follow the disease relapse
and adjust adjuvant therapy accordingly and that the arsenal of target specific drugs
should be sufficient to control cancer with marginal negative side effects to patients
[134]. RNA-seq is still expensive, however, contextual knowledge should allow therapy
design based only on a few representative protein markers that could be clinically mon-
itored by Ampliseq at low cost.
PM implies precision therapy, which means that cytotoxic drugs should ideally be re-
duced to a reasonable minimum and substituted by target-specific drugs as much as
possible. In this connection, nanoparticles hold great promise and can be used to ad-
ministrate drugs and siRNAs. The Genomics of Drug Sensitivity in Cancer (GDSC)
database (www.cancerRxgene.org) is a powerful tool for such design; it is freely avail-
able and currently contains drug sensitivity data for almost 75,000 experiments, de-
scribing response to 138 anticancer drugs across almost 700 cancer cell lines [207];
another interesting resource in that respect is the Cancer Cell Line Encyclopedia [208].
With the fast pace of modern technology development, we can make a safe prediction
that at some point in a not-too-distant future, when a patient is diagnosed with cancer,
it will be possible to rapidly and inexpensively sequence both malignant and normal
cells through biopsy in order to inform the treatment plan. When specific oncotargets
are identified, it will become theoretically possible to define a personalized drug cock-
tail on the basis of existing knowledge or even, on-the-fly, by in silico simulations
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(docking and molecular dynamics) of inhibitors with these oncotargets. Theoretically,
this strategy is compatible with personalized medicine, in the sense, that whenever the
strategy is designed, it can be, in principle, largely automated. Since the response rate
to a specific chemotherapeutic drug might be relatively low in an unselected pre-
treated patient population, it is a pre-requisite that the repurposing strategy includes
pre-selection of those patients with a favorable molecular profile in their cancer cells,
i.e., those patients with the highest likelihood of benefiting from the treatment. The
strategy proposed by Carels et al. [134] differs from the traditional view of drug repur-
posing in expecting to find new indications for cocktail therapies that should affect es-
sential pathways/mechanisms resulting in cancer cell death with minimal side effects
for normal cells. In other words, the aim is to simultaneously maximize efficacy and
minimize toxicity of a given treatment regimen. This strategy is expected to overcome
intrinsic and acquired resistance, tumor heterogeneity, adaptation, and genetic instabil-
ity of cancer cells.
Finally, pharmacogenetics is another PM dimension that cannot be neglected since a
target specific drug can be effective for a given patient and not for another according
to its particular profile of genetic polymorphism, which means that several drug alter-
natives must be available for a same target.
Conclusions
The fundamental recognition that cancer is caused by the unregulated expansion of cells
because of their somatic mutations has however contributed only a little to its treatment
and it is not obvious that it can improve patient outcomes. A mutation-oriented view is
not necessarily very productive in that respect. Indeed, mutations have indirect pleiotropic
effects on the regulation of other genes. What must be considered is that cancer is a dis-
ease of cellular regulation pathways. Consequently, we propose that it is the signaling
phenotype of dysregulated cancer cells that is the key feature to be addressed in order to
achieve success in cancer precision therapy. The characterization of cancer-activated pro-
tein networks will guide combination therapies to optimize therapeutic effects with the
consequence that a shift towards PM from the current SM approach will improve the
clinical benefit to patients. However, the failure to deliver PM is often associated with the
lack of specific drugs for the case under consideration. Thus, oncology is at the frontline
of PM, moving into the use of molecular profile of individuals’ genomes to optimize their
disease management and to avoid over- and under-treatment, which is common to trad-
itional chemotherapy based on the SM approach, thus reducing toxicities associated with
nonspecific modes of action of chemotherapy.
A key challenge associated with PM of cancer diseases is the heterogeneity of tumors
and progressive phenotype drifting of their malignant cells that complicates precision
diagnosis and therapies with the consequence that a single snap-shot biopsy at a single
time-point may not be sufficient. Malignant cell resistance to drugs has resulted in the
selection of an arsenal of cytotoxic drugs with severe side effects for patients. However,
the combination of targeted therapies and the stimulation of the immune system could
help in the process of malignant cell eradication. In addition, the rise of high through-
put technologies for cell and molecular diagnosis at RNA/DNA and protein levels has
raised hopes for precision medicine. The comparison of transcriptome profiling from
malignant cells, neighbor stroma cells, and healthy cells potentially allows the
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identification of key hub targets involved in the malignant pathway rewiring. On-the-fly
selection of target-specific drugs for disease-specific protein hubs is now theoretically
feasible in the context of precision medicine. Biosensor technology is also rapidly im-
proving and one may readily conclude that liquid biopsy will allow the non-invasive
diagnosis and real-time monitoring of cancer evolution.
Despite its apparent high costs, PM must be pursued in the context of translational
medicine simply due to ethical issues for patients, but also due to high cost incurred by
the prescription of ineffective drug therapies in refractory patients and, finally, due to
the social costs associated with cytotoxic therapies plagued by poor clinical outcomes
and debilitating side effects. The European Medicines Agency guideline on anticancer
drug evaluation already recommends the development of biomarker diagnostic
methods early in clinical development, which makes irreversible the ongoing trend to-
ward the PM approach of cancer [209]. Collaborative international programs with the
purpose of evaluating PM approach for BC treatment, such as the umbrella study
(which assesses the effect of different drugs in different molecular alterations either in
one or several tumours) termed AURORA [210], have already been launched. As the
era of stratified oncology moves into the era of PM, there is an urgent need for the in-
tegration of large-scale genomic and clinical data into information to serve as guidance
to clinical decisions.
Abbreviations
A: adenine; BC: breast cancer; BCSC: breast cancer stem cell; CAM: cell adhesion molecules; CAR: chimeric antigen
receptor; CD: clusters of differentiation; CDK: cyclin-dependent kinases; CpG: a cytosine followed by a guanine;
CTL: cytotoxic T lymphocyte; EC: endothelial cell; EM: extracellular matrix; EMT: epithelial-mesenchymal transition;
EPC: endothelial progenitor cell; ER: estrogen receptor; GC: guanine plus cytosine; GI50: half cell growth inhibition;
GO: gene ontology; GRN: gene regulatory networks; HER2: epidermal growth factor receptor 2; HTS: high-throughput
drug screen; LCM: laser capture microdissection; MET: mesenchymal-epithelial transition; MMEJ: microhomology-
mediated end joining; NGS: next generation sequencing; PM: precision medicine; PPI: protein-protein interaction;
PR: progesterone receptor; SC: stem cell; T: thymine; TAM: tumor-associated macrophages; TCR: T cell receptor;
TN: triple-negative; Y2H: yeast two-hybrid.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
NC conceived and wrote the manuscript with LS, TT and JT. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by a fellowship from CAPES-Fiocruz (cooperation term 001/2012 CAPES-Fiocruz) to T. M. Tilli,
the National Institute for Science and Technology on Innovation on Neglected Diseases (INCT/IDN, CNPq, 573642/
2008-7), the Canadian Breast Cancer Foundation, the Allard Foundation and the Alberta Cancer Foundation.
Author details
1Laboratório de Modelagem de Sistemas Biológicos, National Institute of Science and Technology for Innovation in
Neglected Diseases (INCT/IDN, CNPq), Centro de Desenvolvimento Tecnológico em Saúde, Fundação Oswaldo Cruz,
Rio de Janeiro, Brazil. 2Department of Oncology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, AB
T6G 1Z2, Canada. 3Department of Physics, University of Alberta, Edmonton, AB T6G 2E1, Canada.
Received: 8 November 2015 Accepted: 15 February 2016
References
1. Cecilio AP, Takakura ET, Jumes JJ, Dos Santos JW, Herrera AC, Victorino VJ, et al. Breast cancer in Brazil:
epidemiology and treatment challenges. Breast Cancer. 2015;7:43–9. doi:10.2147/BCTT.S50361.
2. Rahman M, Hasan MR. Cancer metabolism and drug resistance. Metabolites. 2015;5(4):571–600. doi:10.3390/
metabo5040571.
3. Arnedos M, Vicier C, Loi S, Lefebvre C, Michiels S, Bonnefoi H, et al. Precision medicine for metastatic breast
cancer—limitations and solutions. Nat Rev Clin Oncol. 2015;12(12):693–704. doi:10.1038/nrclinonc.2015.123.
4. Lu YF, Goldstein DB, Angrist M, Cavalleri G. Personalized medicine and human genetic diversity. Cold Spring Harb
Perspect Med. 2014;4(9):a008581.
Carels et al. Theoretical Biology and Medical Modelling  (2016) 13:7 Page 40 of 46
5. Ciardiello F, Arnold D, Casali PG, Cervantes A, Douillard J-Y, Eggermont A, et al. Delivering precision
medicine in oncology today and in future — the promise and challenges of personalised cancer
medicine: a position paper by the European Society for Medical Oncology (ESMO). Ann Oncol. 2014;25:
1673–8. doi:10.1093/annonc/mdu217.
6. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
7. Wahle KW, Brown I, Rotondo D, Heys SD. Plant phenolics in the prevention and treatment of cancer. Adv Exp
Med Biol. 2010;698:36–51.
8. Liu RH. Potential synergism of phytochemicals in cancer prevention: mechanisms of action. J Nutr. 2004;134:3479S–85S.
9. Fresco P, Borges F, Diniz C, Marques MP. New insights into the anticancer properties of polyphenols. Med Res Rev.
2006;26:747–66.
10. Aggarwal BB, Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem
Pharmacol. 2006;71:1397–421.
11. Pelekanou V, Leclercq G. Recent insights into the effect of natural and environmental estrogens on mammary
development and carcinogenesis. Int J Dev Biol. 2011;55:869–78. doi:10.1387/ijdb.113369vp.
12. Richert MM, Schwertfeger KL, Ryder JW, Anderson SM. An atlas of mouse mammary gland development.
J Mammary Gland Biol Neoplasia. 2000;5:227–41.
13. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15:1010–2.
14. Travers MT, Barber MC, Tonner E, Quarrie L, Wilde CJ, Flint DJ. The role of prolactin and growth hormone in the
regulation of casein gene expression and mammary cell survival: relationships to milk synthesis and secretion.
Endocrinology. 1996;137:1530–9.
15. Brisken C, Rajaram RD. Alveolar and lactogenic differentiation. J Mammary Gland Biol Neoplasia. 2006;11:239–48.
16. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy
for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.
17. Su Y, Subedee A, Bloushtain-Qimron N, Savova V, Krzystanek M, Li L, et al. Somatic cell fusions reveal extensive
heterogeneity in basal-like breast cancer. Cell Reports. 2015;11:1549–63.
18. Vaz-Luis I, Ottesen RA, Hughes ME, Mamet R, Burstein HJ, Edge SB, et al. Outcomes by tumor subtype and
treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol.
2014;32:2142–50.
19. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative
breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.
20. Manuel Iglesias J, Beloqui I, Garcia-Garcia F, Leis O, Vazquez-Martin A, Eguiara A, et al. Mammosphere formation in
breast carcinoma cell lines depends upon expression of E-cadherin. PLoS One. 2013;8(10):e77281. doi:10.1371/
journal.pone.0077281.
21. Weissenstein U, Schumann A, Reif M, Link S, Toffol-Schmidt UD, Heusser P. Detection of circulating tumor cells in
blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies. BMC
Cancer. 2012;12:206.
22. Mannello F. Understanding breast cancer stem cell heterogeneity: time to move on to a new research paradigm.
BMC Med. 2013;11:169.
23. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and
transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003;17(10):1253–70.
24. Ghebeh H, Sleiman GM, Manogaran PS, Al-Mazrou A, Barhoush E, Al-Mohanna FH, et al. Profiling of normal and
malignant breast tissue show CD44high/CD24low phenotype as a predominant stem/progenitor marker when used
in combination with Ep-CAM/CD49f markers. BMC Cancer. 2013;13:289.
25. Kosaka PM, Pini V, Ruz JJ, da Silva RA, González MU, Ramos D, et al. Detection of cancer biomarkers in serum
using a hybrid mechanical and optoplasmonic nanosensor. Nat Nanotechnol. 2014;9(12):1047–53.
26. Liang L, Deng L, Chen Y, Li GC, Shao C, Tischfield JA. Modulation of DNA end joining by nuclear proteins. J Biol
Chem. 2005;280(36):31442–9.
27. Hornsby C, Page KM, Tomlinson IP. What can we learn from the population incidence of cancer? Armitage Doll
revisited Lancet Oncol. 2007;8:1030–8.
28. Jiang Y, Pjesivac-Grbovic J, Cantrell C, Freyer JP. A multiscale model for avascular tumor growth. Biophys J. 2005;
89:3884–94.
29. Menchon SA, Condat CA. Cancer growth: predictions of a realistic model. Phys Rev E Stat Nonlin Soft Matter Phys.
2008;78:022901.
30. Wallace DI, Guo X. Properties of tumor spheroid growth exhibited by simple mathematical models. Frontiers
Oncol. 2013. doi:10.3389/fonc.2013.00051.
31. Frieboes HB, Zheng X, Sun C-H, Tromberg B, Gatenby R, Cristini V. An integrated computational/experimental
model of tumor invasion. Cancer Res. 2006;66:1597–604.
32. Stamper IJ, Byrne HM, Owen MR, Maini PK. Modelling the role of angiogenesis and vasculogenesis in solid tumour
growth. Bull Math Biol. 2007;69:2737–72.
33. Bacac M, Stamenkovic I. Metastatic cancer cell. Annu Rev Pathol. 2008;3:221–47. doi:10.1146/annurev.pathmechdis.
3.121806.151523.
34. Friesen DE, Baracos VE, Tuszynski JA. Modeling the energetic cost of cancer as a result of altered energy
metabolism: implications for cachexia. Theor Biol Med Model. 2015;12:17. doi:10.1186/s12976-015-0015-0.
35. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, et al. Initial genome sequencing and
analysis of multiple myeloma. Nature. 2011;471:467–72.
36. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, et al. Signatures of mutational processes in
human cancer. Nature. 2013;500:415–21.
37. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P, et al. An APOBEC cytidine deaminase
mutagenesis pattern is widespread in human cancers. Nat Genet. 2013;45(9):970–6. doi:10.1038/ng.2702.
38. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer
evolution. Nature. 2013;501(7467):338–45.
Carels et al. Theoretical Biology and Medical Modelling  (2016) 13:7 Page 41 of 46
39. Burrell RA, Juul N, Johnston SR, Reis-Filho JS, Szallasi Z, Swanton C. Targeting chromosomal instability and tumour
heterogeneity in HER2-positive breast cancer. J Cell Biochem. 2010;111(4):782–90.
40. Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution in breast cancer revealed by single
nucleus genome sequencing. Nature. 2014;512:155–60.
41. Nik-Zainal S, Van Loo P, Wedge DC, Alexandrov LB, Greenman CD, Lau KW, et al. The life history of 21 breast
cancers. Cell. 2012;149:994–1007.
42. Comai L. The advantages and disadvantages of being polyploid. Nat Rev Genet. 2005;6(11):836–46.
43. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, et al. The origin and evolution of mutations in acute
myeloid leukemia. Cell. 2012;150:264–78.
44. de Bruin EC, Taylor TB, Swanton C. Intra-tumor heterogeneity: lessons from microbial evolution and clinical
implications. Genome Med. 2013;5:101.
45. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306–13.
46. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched
evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92. doi:10.1056/NEJMoa1113205.
47. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer.
Oncogene. 2010;29:4741–51.
48. Demidenko E. The assessment of tumour response to treatment. Appl Stat. 2006;55:365–77.
49. Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED, et al. Epithelial - mesenchymal and
mesenchymal - epithelial transitions in carcinoma progression. J Cell Physiol. 2007;213:374–83.
50. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144:646–74.
51. Wertz IE, Dixit VM. Regulation of death receptor signaling by the ubiquitin system. Cell Death Differ. 2010;17:14–
24.
52. Sudarsanam S, Johnson DE. Functional consequences of mTOR inhibition. Curr Opin Drug Discov Devel. 2010;13:
31–40.
53. Curto M, Cole BK, Lallemand D, Liu CH, McClatchey AI. Contact-dependent inhibition of EGFR signaling by Nf2/
Merlin. J Cell Biol. 2007;177:893–903.
54. Okada T, Lopez-Lago M, Giancotti FG. Merlin/NF-2 mediates contact inhibition of growth by suppressing
recruitment of Rac to the plasma membrane. J Cell Biol. 2005;171:361–71.
55. Cooper S, Shayman JA. Revisiting retinoblastoma protein phosphorylation during the mammalian cell cycle. Cell
Mol Life Sci. 2001;58:580–95.
56. Burkhart DL, Sage J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer.
2008;8:671–82.
57. Collado M, Serrano M. Senescence in tumours: evidence from mice and humans. Nat Rev Cancer. 2010;10:51–7.
58. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis. 2010;31:9–18.
59. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet. 2005;6:611–22.
60. Shay JW, Wright WE. Hayflick, his limit, and cellular ageing. Nat Rev Mol Cell Biol. 2000;1:72–6.
61. Raynaud CM, Hernandez J, Llorca FP, Nuciforo P, Mathieu MC, Commo F, et al. DNA damage repair and telomere
length in normal breast, preneoplastic lesions, and invasive cancer. Am J Clin Oncol. 2010;33:341–5.
62. Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb
Hemost. 2010;36:321–31.
63. Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol. 2009;29:789–91.
64. Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal
development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117–34.
65. Taube JH, Herschkowitz JI, Komurov K, Zhou AY, Gupta S, Yang J, et al. Core epithelial- to-mesenchymal transition
interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.
Proc Natl Acad Sci U S A. 2010;107:15449–54.
66. Hlubek F, Brabletz T, Budczies J, Pfeiffer S, Jung A, Kirchner T. Heterogeneous expression of Wnt/beta-catenin
target genes within colorectal cancer. Int J Cancer. 2007;121:1941–8.
67. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res.
2010;70:5649–69.
68. McGowan PM, Kirstein JM, Chambers AF. Micrometastatic disease and metastatic outgrowth: clinical issues and
experimental approaches. Future Oncol. 2009;5:1083–98.
69. Berx G, van Roy F. Involvement of members of the cadherin superfamily in cancer. Cold Spring Harb Perspect Biol.
2009;1:a003129.
70. Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordón-Cardo C, et al. Identifying sitespecific metastasis genes
and functions. Cold Spring Harb Symp Quant Biol. 2005;70:149–58.
71. Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11:393–410.
72. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: Metabolic reprogramming fuels
cell growth and proliferation. Cell Metab. 2008;7:11–20.
73. Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev. 2009;23:
537–48.
74. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
75. Kennedy KM, Dewhirst MW. Tumor metabolism of lactate: the influence and therapeutic potential for MCT and
CD147 regulation. Future Oncol. 2010;6:127–48.
76. Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer
cells. Radiother Oncol. 2009;92:329–33.
77. DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed
cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis.
Proc Natl Acad Sci U S A. 2007;104:19345–50.
78. Teng MWL, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with
cancer. J Leukoc Biol. 2008;84:988–93.
Carels et al. Theoretical Biology and Medical Modelling  (2016) 13:7 Page 42 of 46
79. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology.
2007;121:1–14.
80. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor
microenvironment and progression. Trends Immunol. 2010;31:220–7.
81. Shields JD, Kourtis IC, Tomei AA, Roberts JM, Swartz MA. Induction of lymphoidlike stroma and immune escape by
tumors that express the chemokine CCL21. Science. 2010;328:749–52.
82. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell. 2010;40:179–204.
83. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883–99.
84. Galluzzi L, Kroemer G. Necroptosis: a specialized pathway of programmed necrosis. Cell. 2008;135:1161–3.
85. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 2010;
141:52–67.
86. Palermo C, Joyce JA. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol Sci.
2008;29:22–8.
87. Wyckoff JB, Wang Y, Lin EY, Li JF, Goswami S, Stanley ER, et al. Direct visualization of macrophage- assisted tumor
cell intravasation in mammary tumors. Cancer Res. 2007;67:2649–56.
88. Hanahan D, Coussens LM. Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment.
Cancer Cell. 2012;21:309–22.
89. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL. Transforming growth factor-beta signaling-deficient fibroblasts
enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
Mol Cancer Res. 2008;6:1521–33.
90. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332–7.
91. Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol. 2013;
10(4):191–210. doi:10.1038/nrclinonc.2013.29.
92. Daniele G, Corral J, Molife LR, de Bono JS. FGF receptor inhibitors: role in cancer therapy. Curr Oncol Rep. 2012;
14(2):111–9. doi:10.1007/s11912-012-0225-0.
93. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: From a
biologic rationale to medical perspectives. Cancer Discov. 2013;3(3):264–79.
94. Xue M, Cao X, Zhong Y, Kuang D, Liu X, Zhao Z, et al. Insulin-like growth factor-1 receptor (IGF-1R) kinase
inhibitors in cancer therapy: advances and perspectives. Curr Pharm Des. 2012;18(20):2901–13.
95. Chen HX, Sharon E. IGF-1R as an anti-cancer target—trials and tribulations. Chinese J Cancer. 2013;32(5):242–52.
96. Laplante M, Sabatini DM. Regulation of mTORC1 and its impact on gene expression at a glance. J Cell Sci. 2013;
126(8):1713–9.
97. Dienstmann R, Rodon J, Serra V, Tabernero J. Picking the Point of Inhibition: A comparative review of PI3K/AKT/
mTOR pathway inhibitors. Mol Cancer Ther. 2014;13(5):1021–31.
98. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, et al. Mitogen-activated protein (MAP)
kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22(2):153–83.
99. Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert
Opin Ther Targets. 2012;16(1):103–19.
100. Organ SL, Tsao M-S. An overview of the c-MET signaling pathway. de Bono JS, ed. Therapeutic Advances Med
Oncol. 2011;3(1 Suppl):S7–S19. doi:10.1177/1758834011422556.
101. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in
cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–46.
102. Epstein EH, De Sauvage FJ, Xie J, Murone M, Luoh S-M, Ryan A, et al. Activating Smoothened mutations in
sporadic basal-cell carcinoma. Nature. 1998;391(6662):90–2.
103. Onishi H, Katano M. Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. World J
Gastroenterol. 2014;20(9):2335–42.
104. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis. 2008;4(2):68–75.
105. Logan CW, Nusse R. The Wnt signaling pathway in development and disease. Cell Dev Bio. 2004;20:781–810.
106. Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13:11–26.
107. Jain S, Santa-Maria CA, Gradishar WJ. The role of ovarian suppression in premenopausal women with hormone
receptor-positive early-stage breast cancer. Oncology. 2015;29(7):473–8. 481.
108. Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in
premenopausal women. Cochrane Database Syst Rev. 2009;4:CD004562. doi:10.1002/14651858.CD004562.pub4.
109. Diaby V, Tawk R, Sanogo V, Xiao H, Montero AJ. A review of systematic reviews of the cost-effectiveness of
hormone therapy, chemotherapy, and targetedtherapy for breast cancer. Breast Cancer Res Treat. 2015;151(1):27–
40.
110. Lumachi F, Santeufemia DA, Basso SM. Current medical treatment of estrogen receptor-positive breast cancer.
World J Biol Chem. 2015;6(3):231–9. doi:10.4331/wjbc.v6.i3.231.
111. Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast
cancer. N Engl J Med. 2015;373(3):209–19.
112. Zelnak AB, O’Regan RM. Optimizing endocrine therapy for breast cancer. J Natl Compr Canc Netw. 2015;13(8):e56–
64.
113. Mittendorf EA, Peoples GE, Singletary SE. Breast cancer vaccines: promise for the future or pipe dream? Cancer.
2007;110:1677–86.
114. Criscitiello C, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, et al. Immune approaches to the treatment
of breast cancer, around the corner? Breast Cancer Res. 2014;16(1):204.
115. Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, et al. Redirected antitumor activity of
primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther. 2012;20:
633–43.
116. Liang XJ, Chen C, Zhao Y, Wang PC. Circumventing tumor resistance to chemotherapy by nanotechnology.
Methods Mol Biol. 2010;596:467–88.
Carels et al. Theoretical Biology and Medical Modelling  (2016) 13:7 Page 43 of 46
117. McNeil SE. Nanotechnology for the biologist. J Leukoc Biol. 2005;78:585–94.
118. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with
phospholipidanchored folic acid-PEG conjugates. Adv Drug Deliv Rev. 2004;56:1177–92.
119. Stella B, Arpicco S, Peracchia MT, Desmaële D, Hoebeke J, Renoir M, et al. Design of folic acid-conjugated
nanoparticles for drug targeting. J Pharm Sci. 2000;89:1452–64.
120. Brigui I, Djavanbakht-Samani T, Jolles B, Pigaglio S, Laigle A. Minimally modified phosphodiester antisense
oligodeoxyribonucleotide directed against the multidrug resistance gene mdr1. Biochem Pharmacol. 2003;65:747–54.
121. Shoji Y, Nakashima H. Current status of delivery systems to improve target efficacy of oligonucleotides. Curr
Pharm Des. 2004;10:785–96.
122. Davis ME, Zuckerman JE, Choi CH, Seligson D, Tolcher A, Alabi CA, et al. Evidence of RNAi in humans from
systemically administered siRNA via targeted nanoparticles. Nature. 2010;464(7291):1067–70.
123. Garcia-Ojalvo J, Martinez AA. Towards a statistical mechanics of cell fate decisions. Curr Opin Genetics Dev. 2012;
22:619–26.
124. Ying Q-L, Wray J, Nichols J, Batlle-Morera L, Doble B, Woodgett J, et al. The ground state of embryonic stem cell
self-renewal. Nature. 2008;453:519–23.
125. Rolland T, Taşan M, Charloteaux B, Pevzner SJ, Zhong Q, Sahni N, et al. A proteome-scale map of the human
interactome network. Cell. 2014;159(5):1212–26.
126. Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabási AL. The human disease network. Proc Natl Acad Sci U S A.
2008;104(21):8685–90.
127. Mardis ER, Wilson RK. Cancer genome sequencing: a review. Hum Mol Genet. 2009;18(2):R163–8.
128. Liu X, Wang J, Chen L. Whole-exome sequencing reveals recurrent somatic mutation networks in cancer. Cancer
Lett. 2013;340(2):270–6.
129. Esteller M. Aberrant DNA, methylation as a cancer-inducing mechanism. Annu Rev Pharmacol Toxicol. 2005;45:
629–56.
130. Meaburn E, Schulz R. Next generation sequencing in epigenetics: insights and challenges. Semin Cell Dev Biol.
2012;23(2):192–9.
131. Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, Baselga J, Berger MF, Ladanyi M. Precision medicine at
Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted
therapy trials. Drug Discov Today. 2015. doi: 10.1016/j.drudis.2015.08.005.
132. West J, Bianconi G, Severini S, Teschendorff AE. Differential network entropy reveals cancer system hallmarks. Sci
Rep. 2012;2:802.
133. Carels N, Tilli T, Tuszynski JA. A computational strategy to select optimized protein targets for drug development
toward the control of cancer diseases. PLoS One. 2015;10(1):e0115054.
134. Carels N, Tilli T, Tuszynski JA. Optimization of combination chemotherapy based on the calculation of network
entropy for protein-protein interactions in breast cancer cell lines. EPJ Nonlinear Biomed Physics. 2015;3:6.
135. Gabrovska PN, Smith RA, Haupt LM, Griffiths LR. Gene expression profiling in human breast cancer – toward
personalised therapeutics? Open Breast Cancer J. 2010;2:46–59.
136. Ransohoff DF. How to improve reliability and efficiency of research about molecular markers: roles of phases,
guidelines, and study design. J Clin Epidemiol. 2007;60(12):1205–19.
137. EGAPP (Evaluation of Genomic Applications in Practice and Prevention) Working Group. Recommendations from
the EGAPP Working Group: can tumor gene expression profiling improve outcomes in patients with breast
cancer? Genet Med. 2009;11(1):66–73.
138. Abba MC, Lacunza E, Butti M, Aldaz CM. Breast cancer biomarker discovery in the functional genomic age: A
systematic review of 42 gene expression signatures. Biomark Insights. 2010;5:103–18.
139. Islam S, Kjällquist U, Moliner A, Zajac P, Fan J-B, Lönnerberg P, et al. Characterization of the single-cell
transcriptional landscape by highly multiplex RNA-seq. Genome Res. 2011;21:1160–7.
140. Cui Y, Irudayaraj J. Advanced ReviewInside single cells: quantitativeanalysis with advanced opticsand
nanomaterials. WIREs Nanomed Nanobiotechnol. 2015;7(3):387–407. doi:10.1002/wnan.1321.
141. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by
RNA-Seq. Nat Methods. 2008;5:621–8.
142. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density
oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185–93.
143. Amemiya Y, Bacopulos S, Al-Shawarby M, Al-Tamimi D, Naser W, Ahmed A, et al. A comparative analysis of breast
and ovarian cancer-related gene mutations in Canadian and Saudi Arabian patients with breast cancer. Anticancer
Res. 2015;35:2601–10.
144. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.
145. Wang V, Wu W. MicroRNA: A new player in breast cancer development. J Cancer Mol. 2007;3(5):133–8.
146. Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. MicroRNAs exhibit high frequency
genomic alterations in human cancer. Proc Natl Acad Sci U S A. 2006;103:9136–41.
147. Kent OA, Mendell JT. A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.
Oncogene. 2006;25:6188–96.
148. Wilhelm M, Schlegl J, Hahne H, Gholami AM, Lieberenz M, Savitski MM, et al. Mass-spectrometry-based draft of the
human proteome. Nature. 2014;509:582–7.
149. Sharma K, D’Souza RC, Tyanova S, Schaab C, Wiśniewski JR, Cox J, et al. Ultradeep human phosphoproteome
reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep. 2014;8(5):1583–94.
150. Lawrence RT, Perez EM, Hernández D, Miller CP, Haas KM, Irie HY, et al. The proteomic landscape of triple-negative
breast cancer. Cell Rep. 2015;11(4):630–44.
151. Eyckerman S, Verhee A, Van der Heyden J, Lemmens I, Ostade XV, Vandekerckhove J, et al. Design and application
of a cytokine-receptor-based interaction trap. Nat Cell Biol. 2001;3:1114–9.
152. Dreze M, Monachello D, Lurin C, Cusick ME, Hill DE, Vidal M, et al. High-quality binary interactome mapping.
Methods Enzymol. 2010;470:281–315.
Carels et al. Theoretical Biology and Medical Modelling  (2016) 13:7 Page 44 of 46
153. Cusick ME, Yu H, Smolyar A, Venkatesan K, Carvunis A-R, Simonis N, et al. Literature-curated protein interaction
datasets. Nat Methods. 2009;6:39–46.
154. Rietman E, Bloemendal A, Platig J, Tuszynski J, Klement GL. Gibbs free energy of protein-protein interactions
reflects tumor stage. doi:10.1101/022491.
155. Banerji CR, Miranda-Saavedra D, Severini S, Widschwendter M, Enver T, Zhou JX, et al. Cellular network entropy as
the energy potential in Waddington’s differentiation landscape. Sci Rep. 2013;3:3039.
156. Breitkreutz D, Hlatky L, Rietman E, Tuszynski JA. Molecular signaling network complexity is correlated with cancer
patient survivability. Proc Natl Acad Sci U S A. 2012;109(23):9209–12.
157. Teschendorff AE, Severini S. Increased entropy of signal transduction in the cancer metastasis phenotype. BMC
Syst Biol. 2010;4:104.
158. Demetrius L, Manke T. Robustness and network evolution - an entropic principle. Physica A. 2005;346:682–96.
159. Barabási AL, Oltvai ZN. Network biology: understanding the cell’s functional organization. Nat Rev Genet.
2004;5(2):101–13.
160. Jeong H, Mason SP, Barabási AL, Oltvai ZN. Lethality and centrality in protein networks. Nature. 2001;411(6833):41–2.
161. Eisenberg E, Levanon EY. Preferential attachment in the protein network evolution. Phys Rev Lett. 2003;91:138701.
162. Milo R, Shen-Orr SS, Itzkovitz S, Kashtan N, Alon U. Network motifs: simple building blocks of complex networks.
Science. 2002;298:824–7.
163. Cohen R, Havlin S. Scale-free networks are ultra small. Phys Rev Lett. 2003;90:058701.
164. Maslov S, Sneppen K. Specificity and stability in topology of protein networks. Science. 2002;296:910–3.
165. Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabási A-L. Hierarchical organization of modularity in metabolic
networks. Science. 2002;297:1551–5.
166. Holme P, Huss M, Jeong H. Subnetwork hierarchies of biochemical pathways. Bioinformatics. 2003;19:532–8.
167. Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature. 2000;406(6794):378–82.
168. Yeger-Lotem E, Sattath S, Kashtan N, Itzkovitz S, Milo R, Pinter RY, et al. Network motifs in integrated cellular
networks of transcription-regulation and protein-protein interaction. Proc Natl Acad Sci U S A.
2004;101(16):5934–9.
169. de Matos SR, Emmert-Streib F. Bagging statistical network inference from large-scale gene expression data. PLoS
One. 2012;7(3):e33624.
170. Mahesh S, Mangla N, Pooja V, Bhyratae SA. Reconstruction of Gene Regulatory Network to identify prognostic
molecular markers of the reactive stroma of breast and prostate cancer using information theoretic approach. Int
J Innovative Res Comput Commun Eng. 2015;3(10):303–10.
171. Madhamshettiwar PB, Maetschke SR, Davis MJ, Reverter A, Ragan MA. Gene regulatory network inference:
evaluation and application to ovarian cancer allows the prioritization of drug targets. Genome Med. 2012;4(5):41.
172. Fumiã HF, Martins ML. Boolean network model for cancer pathways: predicting carcinogenesis and targeted
therapy outcomes. PLoS One. 2013;8(7):e69008.
173. Kitano H. Biological robustness. Nat Rev Genet. 2004;5(11):826–37.
174. Kitano H. Towards a theory of biological robustness. Mol Syst Biol. 2007;3:137.
175. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, et al. Subtype and pathway specific responses to
anticancer compounds in breast cancer. Proc Natl Sci Acad USA. 2012;109:2724.
176. Parise CA, Caggiano V. Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification
according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol. 2014;2014:469251.
177. Kapoor S, Rallabandi VP, Sakode C, Padhi R, Roy PK. A patient-specific therapeutic approach for tumour cell
population extinction and drug toxicity reduction using control systems-based dose-profile design. Theor Biol
Med Model. 2013;10:68. doi:10.1186/1742-4682-10-68.
178. Lehár J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, et al. Chemical combination effects
predict connectivity in biological systems. Mol Syst Biol. 2007;3:80.
179. Koizumi Y, Iwami S. Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal
combinations of antiviral drugs. Theor Biol Med Model. 2014;11:41. doi:10.1186/1742-4682-11-41.
180. Yurkiewicz S. The prospects for personalized medicine. Hastings Cent Rep. 2010;40:14–6.
181. Langreth R, Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile.
Oncologist. 1999;4(5):426–7.
182. Schleidgen S, Klingler C, Bertram T, Rogowski WH, Marckmann G. What is personalized medicine: sharpening a
vague term based on a systematic literature review. BMC Med Ethics. 2013;21:14–55.
183. Redekop WK, Mladsi D. The faces of personalized medicine: a framework for understanding its meaning and
scope. Value Health. 2013;16(6):S4–9.
184. Burke W, Brown Trinidad S, Press NA. Essential elements of personalized medicine. Urol Oncol. 2014;32(2):193–7.
185. McGowan ML, Settersten Jr RA, Juengst ET, Fishman JR. Integrating genomics into clinical oncology: ethical and
social challenges from proponents of personalized medicine. Urol Oncol. 2014;32(2):187–92.
186. Tavassoli FA, Millis RR, Boecker W, Lakhani SR. Lobular Neoplasia. In: Tavassoli FA, Devilee P, et al., editors. World
Health Organization classification of tumours. Lyon, France: IARC Press; 2003. p. 60–2.
187. Almendro V, Fuster G. Heterogeneity of breast cancer: etiology and clinical relevance. Clin Transl Oncol. 2011;
13(11):767–73.
188. Karczewski KJ, Daneshjou R, Altman RB. Chapter 7: Pharmacogenomics. PLoS Comput Biol. 2012;8(12):e1002817.
189. Jain KK. Personalised medicine for cancer: from drug development into clinical practice. Expert Opin
Pharmacother. 2005;6(9):1463–76.
190. Workman P. New drug targets for genomic cancer therapy: successes, limitations, opportunities and future
challenges. Curr Cancer Drug Targets. 2001;1(1):33–47.
191. Workman P. The opportunities and challenges of personalized genome-based molecular therapies for cancer:
targets, technologies, and molecular chaperones. Cancer Chemother Pharmacol. 2003;52(1):S45–56.
192. André F, Ciccolini J, Spano JP, Penault-Llorca F, Mounier N, Freyer G, et al. Personalized medicine in oncology:
where have we come from and where are we going? Pharmacogenomics. 2013;14(8):931–9.
Carels et al. Theoretical Biology and Medical Modelling  (2016) 13:7 Page 45 of 46
193. Goldstein JA, de Morais SM. Biochemistry and molecular biology of the human CYP2C subfamily.
Pharmacogenetics. 1994;4(6):285–99.
194. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science.
1999;286(5439):487–91.
195. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. Influence of cytochrome P450 polymorphisms on
drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007;116(3):496–526.
196. EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). Effects of chemotherapy and hormonal therapy for
early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;
365(9472):1687–717.
197. de Vries Schultink AH, Zwart W, Linn SC, Beijnen JH, Huitema AD. Effects of pharmacogenetics on the
pharmacokinetics and pharmacodynamics of tamoxifen. Clin Pharmacokinet. 2015;54(8):797–810.
198. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential
biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6.
J Pharmacol Exp Ther. 2004;310(3):1062–75.
199. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, et al. Pharmacological characterization of 4-
hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat. 2004;85(2):151–9.
200. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects
in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005;55(5):471–8.
201. Phan M, Venitz J. Summary minutes of the Advisory Committee Pharmaceutical Science Clinical Pharmacology
Subcommittee 18–19 Oct 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006-4248m1.pdf.
Accessed 12 Out 2015.
202. Barginear MF, Jaremko M, Peter I, Yu C, Kasai Y, Kemeny M, et al. Increasing tamoxifen dose in breast cancer
patients based on CYP2D6 genotypes and endoxifen levels: effect on active metabolite isomers and the
antiestrogenic activity score. Clin Pharmacol Ther. 2011;90(4):605–11.
203. Damia G, Garattini S. The pharmacological point of view of resistance to therapy in tumors. Cancer Treat Rev.
2014;40(8):909–16.
204. Garattini L, Curto A, Freemantle N. Personalized medicine and economic evaluation in oncology: all theory and no
practice? Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):733–8.
205. Saal LH, Vallon-Christersson J, Häkkinen J, Hegardt C, Grabau D, Winter C, et al. The Sweden Cancerome Analysis
Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast
cancer genomic analyses in the clinical routine. Genome Med. 2015;7(1):20.
206. Legres LG, Janin A, Masselon C, Bertheau P. Beyond laser microdissection technology: follow the yellow brick road
for cancer research. Am J Cancer Res. 2014;4(1):1–28.
207. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of Drug Sensitivity in Cancer
(GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955–61.
208. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia
enables predictive modeling of anticancer drug sensitivity. Nature. 2012;483:603–7.
209. European Commission. Use of ‘-omics’ technologies in the development of personalised medicine. 2013; http://ec.
europa.eu/health/files/latest_news/2013-10_personalised_medicine_en.pdf (10 January 2016, date last accessed).
210. Zardavas D, Maetens M, Irrthum A, Goulioti T, Engelen K, Fumagalli D, et al. The AURORA initiative for metastatic
breast cancer. Br J Cancer. 2014;111(10):1881–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Carels et al. Theoretical Biology and Medical Modelling  (2016) 13:7 Page 46 of 46
